📄

What 46 AI-generated podcasts got wrong about testosterone in women

Private deliverable. Enter the hub password to continue.

That's not right. Try again.

What 46 AI-generated podcasts got wrong about testosterone in women

1,381 high-risk claims from 15.3 hours of audio. Only 32% are supported by papers in the library. One in five is real but overstated.

Prepared 2026-08-05

What this is

Every Audio Overview in the testosterone, menopause and anhedonia notebooks was downloaded, transcribed in full, broken into individual factual claims, and checked against Annette's own research library.

15.3 hours of audio. 46 episodes. 2,561 claims extracted, 1,381 of them high-risk. High-risk means a listener could act on it medically, or it names a number, or it claims prevention of a disease.

Claims were checked against the library, not against the sources NotebookLM says it used. Asking a system's own inputs to grade its own output would hide the failure this was built to find.

The headline

Verdict	Count	Share
SUPPORTED	436	31.6%
OVERSTATED	276	20.0%
CONTRADICTED	65	4.7%
NOT_IN_CORPUS	580	42.0%
ERROR	24	1.7%

Only 32% of high-risk claims are directly supported by a paper in the library. One in five is OVERSTATED: the underlying finding is real, the confidence is not. That group of 276 is the true measure of the problem and it is more than four times the size of the contradictions.

NOT_IN_CORPUS is not a finding against the podcasts. It means the library has nothing to check the claim against. It reflects what Annette holds, not what is true, and 157 of her papers still have no full text at all.

What "VERDICT UNDER REVIEW" means in the tables below

Thirty claims came out of the original run with a verdict but no reason written against it. Those were backfilled on 2026-08-10, using two independent passes over the evidence each verdict already had: one writing the explanation, one judging only whether the retrieved passage addresses the claim at all.

The two passes agree on 7 of the 30. The other 23 are marked VERDICT UNDER REVIEW in place, and each one names its own mismatch. Twelve are cases where the passage does not settle the claim, four retrieved the wrong passage, four look like the evidence actually supports the claim so the verdict itself may be wrong, and three are contradictions filed as mere overstatements.

So the blank was a signal rather than an oversight: the checker left the reason empty roughly where it could not justify itself. Those rows say so now, instead of carrying a fluent rationalization under a verdict that might be wrong.

Read the hit rate here narrowly. These 30 are the audit's weakest rows by construction, being the ones the checker could not explain the first time. How they fared says little about the other 1,351. The full write-up of that backfill is at What happened when the 30 blank verdicts were filled in.

Least trustworthy episodes

Ranked by overstated plus contradicted claims as a share of what was checked. These are the ones to treat as unusable without reading the source first.

Episode	Checked	Overstated	Contradicted	Supported
The Hidden Androgens Your Blood Test Misses	30	17	1	6
Hormone therapy reduces mortality after sixty-five	30	7	7	5
Testosterone rebuilds skin to silence eczema	26	12	0	7
Testosterone Regulates Memory and Mood	32	14	0	11
Why total testosterone is a meaningless metric	37	12	2	16
Progesterone Acts as Literal Brain Armor	45	9	7	6
Why Your Hormone Blood Tests Lie	20	7	0	9
Total testosterone is a biological smokescreen	23	4	4	4
Why Hormone Therapy Stops Midlife Suicide	30	9	1	1
Testosterone, GABA, and Depression in Women	13	3	1	3
Testosterone for female sexual desire	33	6	4	9
Testosterone is the primary female hormone	41	10	2	19
Why testosterone delivery is the drug	25	7	0	10
Age not menopause drives testosterone levels	22	6	0	13

The 276 overstated claims, by subject

This is the section to read before writing a script. Each row is a real finding that the podcast pushed further than the evidence goes. The timecode lets you hear the framing, which is usually where the damage is.

Does it work (78)

Episode	At	Claim	Why it overshoots
Age not menopause drives testosterone levels	16:00	Clinical trials have consistently shown testosterone pharmacotherapy is highly effective at improving sexual desire and arousal in women with distressing low libido.	The passages confirm testosterone improves sexual desire and arousal, but they describe it as effective or significantly improving, not 'highly effective'; the podcast inflates the strength.
Age not menopause drives testosterone levels	16:46	Systematic reviews of randomized placebo-controlled trials show testosterone does not prevent muscle loss, banish brain fog, improve mood, or increase bone density in women.	The podcast claims testosterone does not prevent these outcomes, but the passage only states that systematic reviews have not shown a benefit, which is a weaker conclusion.
Antidepressants for Menopausal Depression_ A Meta-Analysis	5:02	Both SSRIs and SNRIs showed significant benefit over placebo.	The claim that both SSRIs and SNRIs as groups showed significant benefit over placebo is not directly supported; the passages mention efficacy for specific drugs like paroxetine and venlafaxine, but not for the entire classes.
Hormone Therapy and Endometrial Health in Postmenopausal Women	18:58	The protective effect of continuous combined MHT against endometrial cancer is strongest in obese women.	The passage confirms a protective effect in obese women but does not state it is strongest among BMI groups, so the podcast overstates the finding.
Hormone therapy reduces mortality after sixty-five	2:52	A 2004 WHI follow‑up study found that estrogen monotherapy reduced breast cancer by 22%.	The 2004 WHI publication found a non-significant reduction; the statistically significant 22% reduction came from later follow-up analyses, so calling it 'highly significant' in the 2004 study is an overstatement.
Hormone therapy reduces mortality after sixty-five	4:48	Estrogen monotherapy reduced congestive heart failure risk by 5%.	The podcast states the 5% reduction as a causal fact, whereas the source only reports an observational association, and other evidence (e.g., trial data) shows no consistent benefit.
Hormone therapy reduces mortality after sixty-five	10:43	A low dose maintains bone density, vascular health, and symptom relief without causing dangerous clotting.	The claim that low dose 'maintains vascular health' is a stronger assertion than the passage's description of a 'neutral or favorable metabolic and thrombotic profile,' so the claim overstates the evidence.
Hormone therapy reduces mortality after sixty-five	12:09	Non-oral routes are vastly superior for long-term health.	The evidence passage states that newer oral testosterone formulations have safety comparable to non-oral routes, contradicting the podcast's claim that non-oral routes are vastly superior for long-term health. VERDICT UNDER REVIEW: the passage contradicts the claim outright rather than merely overstating it, so OVERSTATED may be too weak.
Hormone therapy reduces mortality after sixty-five	15:35	Transdermal delivery of human-identical estradiol bypasses liver inflammatory response, preventing heart failure, colon cancer, and neurodegeneration.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. Passage only mentions bypassing hepatic metabolism and adverse hepatic effects, not the specific disease preventions (heart failure, colon cancer, neurodegeneration) claimed.
Hormone therapy reduces mortality after sixty-five	15:52	Continuing optimized hormone therapy is a rigorously validated strategy for thriving into the 70s and beyond.	The podcast presents continuing hormone therapy as a rigorously validated strategy for thriving, but the study only supports it as a possible option for carefully selected patients with chronic symptoms, not a broadly validated approach.
Hormones Not Antidepressants For Menopausal Moods	12:19	Irritability, low self-esteem, and social withdrawal significantly improved.	The claim states all three symptoms improved significantly, but the provided study evidence only supports improvements in irritability and social withdrawal, with no mention of low self-esteem.
Hormones Not Antidepressants For Menopausal Moods	16:51	Dose optimization in poor absorbers led to an additional 35-44% reduction in MenOD scores.	The 35% reduction applies to dose optimization, but the 44% figure is from a subgroup adding testosterone, not dose optimization alone, and neither result is specifically linked to poor absorbers.
Hormones Not Antidepressants For Menopausal Moods	18:05	MHT-naive women receiving estrogen, a progestogen, and transdermal testosterone had a 48.53% decrease in global symptom scores.	The study reports a 48.53% reduction for MHT-naïve women initiated on estrogen with or without progesterone plus transdermal testosterone, not specifically for those receiving a progestogen as the claim states.
Hormones Not Antidepressants For Menopausal Moods	19:04	Combination therapy with estrogen, progesterone, and testosterone provides the greatest mood improvement.	The podcast claims the triple combination yields the greatest mood improvement, but the cited study only shows improvement without comparing against other treatments to support that superlative, inflating the finding.
Hormones Not Antidepressants For Menopausal Moods	20:50	Data shows that body-identical hormones are a highly effective, biologically targeted tool for severe mood changes caused by brain withdrawal during menopause.	The study reports significant improvement but describes it as a 'notion' needing further trials; calling it 'highly effective' overstates the strength of the current real-world, retrospective data.
How Fat Turns Testosterone Into Estrogen	17:01	TRT significantly improves sexual desire, restores erectile function, increases lean muscle mass, and reverses insulin resistance.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage addresses improvements in sexual desire, erectile function, and lean body mass but omits any mention of insulin resistance, leaving a key part of the claim unjudgeable.
How Testosterone Protects Women From Alzheimer's	19:27	Resistance exercise is the most accessible and effective lifestyle approach to modulate testosterone levels naturally.	VERDICT UNDER REVIEW. The passage retrieved for this claim does not appear to be about it. The passage only states that both aerobic and resistance training can increase testosterone, not that resistance exercise is the most accessible and effective approach.
How Testosterone Shapes Female Biology	6:43	Testosterone conversion to estradiol is absolutely critical for healthy female fat development.	The passage shows that estradiol production via aromatase influences fat mass in mice, but it does not demonstrate that the conversion is 'absolutely critical' for healthy female fat development; the claim overstates the strength of the evidence from animal studies.
How Testosterone Shapes Female Biology	15:40	In nine-week-old female ARKO mice, deleting the androgen receptor caused zero reduction in total body mass, zero reduction in hindlimb muscle mass, and zero change to adipose fat mass.	The review shows female ARKO mice lacked the reductions seen in males, but it does not specifically claim zero effect at 9 weeks for all three measures, especially adipose, and describes effects as 'limited' rather than absolute zero.
How muscle strength saves your brain	17:26	Anabolic hormones do not work without the mechanical stimulus of exercise.	The passages show mechanical stimulus is critical to enable anabolic processes, but the podcast's claim that hormones 'simply do not work' without it overstates the evidence, which focuses on the necessity of loading to overcome anabolic resistance rather than complete hormonal inefficacy.
Menopausal Depression and Immune Imbalance	25:24	Resveratrol, simvastatin, astragalin are immunomodulatory agents being studied for menopausal depression in models and early human studies.	The podcast presents resveratrol as an immunomodulatory agent studied for menopausal depression in models and early human studies, but the passage only addresses its reproductive effects, not depression, and notes inconsistent clinical outcomes, making the claim overstated for the stated condition.
Menopausal Transition Increases Depression Risk in Later Life	8:22	The risk from menopausal transition remained after accounting for other conditions.	The passage shows that body composition changes during menopause are independent of aging, but the claim generalizes this to 'other conditions' which is not supported by the provided literature.
Menopausal Transition Increases Depression Risk in Later Life	8:27	The association held up after accounting for other diseases.	The podcast claim broadly states an association 'held up after accounting for other diseases,' but the passage shows adjustment for specific clinical factors, not diseases, and is limited to a single study in kidney transplant recipients.
Precision Hormones and Nanotechnology for Depression	2:36	Perimenopausal depression has a hormonal root rather than a purely neurochemical one, which changes the required treatment approach.	The passages support a hormonal component in perimenopausal depression but do not say that this completely changes the treatment approach, so the claim overstates the treatment implications.
Precision Hormones and Nanotechnology for Depression	9:03	In the Glenn study, women on optimized estrogen and progesterone still had brain fog, fatigue, and low mood, indicating these hormones alone were insufficient to restore cognitive function.	The passage confirms persistent symptoms on standard HRT, supporting the insufficiency of estrogen/progesterone alone, but the podcast adds specific symptoms (fatigue) and calls the HRT 'optimized', details not stated in the passage.
Precision Hormones and Nanotechnology for Depression	10:41	Testosterone has profound neuropsychiatric benefits for the female brain.	The claim of 'profound' benefits overstates the evidence, which shows a beneficial effect limited to peri- and postmenopausal women, not a profound or universal neuropsychiatric improvement.
Predicting the right antidepressant with biomarkers	12:00	High systemic inflammation strongly correlates with clinical treatment failure.	The passage shows systemic inflammation predicts morbidity and mortality, but the claim specifies 'clinical treatment failure,' which is a stronger and more specific outcome not directly supported.
Predicting the right antidepressant with biomarkers	16:26	SSRIs often fail to resolve cognitive symptoms of depression even when mood improves.	The claim that cognitive symptoms remain completely untouched is overstated because evidence shows that SSRIs like sertraline can produce modest cognitive improvement, contradicting the absolute language used.
Progesterone Acts as Literal Brain Armor	8:34	For some women, the sudden withdrawal of allo triggers postpartum depression; it is a biological withdrawal syndrome.	The passages show that ALLO withdrawal contributes to postpartum depression only in the context of genetic susceptibility and receptor changes, not as the sole exact trigger.
Progesterone Acts as Literal Brain Armor	9:15	Brexanolone and ziranolone are synthetic allo that provide targeted replacement therapy, instantly engaging GABA receptors and buffering the postpartum allo crash.	The drugs are synthetic analogs, not identical synthetic allopregnanolone, and their effects are not instant but occur within hours.
Progesterone Acts as Literal Brain Armor	9:37	Trial results for severe postpartum depression showed a 70% remission rate within days.	The podcast claims a 70% remission rate, but the cited study only reports rates exceeding 50%, so the claim inflates the actual finding.
Progesterone Acts as Literal Brain Armor	17:35	Patients physically gained hippocampal volume.	The claim is broadly stated, but the evidence only shows hippocampal volume gain in patients with Cushing's disease after treatment, not in patients generally.
Testosterone Regulates Memory and Mood	10:06	ADT impairs working memory and verbal memory.	The studies confirm ADT impairs working memory and verbal memory, but no evidence shows these are the absolute hardest hit domains compared to others like attention or executive function.
Testosterone Regulates Memory and Mood	15:08	In a subset of men with clinically low testosterone, supplementing testosterone alongside standard psychiatric care significantly dropped depression scores.	The podcast claims testosterone supplementation significantly dropped depression scores in men with clinically low testosterone, but the passage states the evidence supporting TRT for clinically relevant depression, even with testosterone deficiency, is not convincing. VERDICT UNDER REVIEW: the passage contradicts the claim outright rather than merely overstating it, so OVERSTATED may be too weak.
Testosterone Regulates Memory and Mood	20:34	Testosterone therapy can pull men out of treatment-resistant depression.	While there is some evidence suggesting a beneficial effect of testosterone on mood in hypogonadal men with refractory depression, the claim that it can 'pull them out' of treatment-resistant depression goes beyond the data presented, which only indicate a possible benefit, not a definitive or strong effect.
Testosterone Therapy for Women's Desire and Mood	0:26	Therapeutic testosterone can improve generalized mood and manage hypoactive sexual desire disorder (HSDD) in women.	Testosterone is recommended for HSDD, but evidence does not support its use for improving generalized mood.
Testosterone Therapy for Women's Desire and Mood	13:32	The Aphrodite trial showed a strong desire signal for testosterone therapy.	The abstract confirms a desire benefit, but describes no magnitude, so stating it was a 'strong' signal overstates the reported finding.
Testosterone Therapy for Women's Desire and Mood	15:17	In premenopausal women without clinical depression, transdermal testosterone significantly improved psychological well-being, overall mood, and sexual function.	The passages support improved sexual function in premenopausal women but do not address psychological well-being or overall mood, making the claim stronger than the evidence.
Testosterone for female sexual desire	7:16	Testosterone therapy is highly effective in postmenopausal women.	The passage states that research supports a moderate therapeutic benefit, not the high effectiveness claimed in the podcast.
Testosterone for female sexual desire	8:05	Studies show a highly significant increase in satisfying sexual events and dramatic improvement in sexual desire.	The studies show statistically significant but modest improvements, not dramatic, in a specific population; the podcast inflates the effect size.
Testosterone for female sexual desire	13:37	Testosterone therapy boosts central arousal and improves local tissue health and lubrication, eliminating pain.	The claim overstates the benefits: testosterone did not boost central arousal (no effect on libido/desire) and pain was only moderately improved, not eliminated.
Testosterone is the primary female hormone	10:55	In one pilot study, 74% of women treated with testosterone pellets remained completely free of migraine attacks.	The claim cites a pilot study with 74% migraine freedom, but the source describes such reports as uncontrolled or small exploratory, indicating the strength of evidence is inflated.
Testosterone is the primary female hormone	19:25	Testosterone pellets might reduce the incidence of breast cancer.	The podcast claims pellets might reduce breast cancer incidence, but the source says such reports are only hypothesis-generating and cannot establish causation, making the claim overstated.
Testosterone rebuilds skin to silence eczema	8:50	Topical testosterone applied three times a week to the neck caused skin severity scores to plummet in both sexes and prevented lesions on treated areas.	The study showed a significant reduction in skin severity scores in rats, not a dramatic 'plummet,' and the podcast omitted that this evidence is from an animal model, inflating the claim's strength.
Testosterone, GABA, and Depression in Women	3:28	Some clinical trials have shown that low-dose testosterone supplements might help improve mood in some women with treatment-resistant depression.	The claim that clinical trials show low-dose testosterone improves mood in women with treatment-resistant depression is overstated because the cited trial found no difference between testosterone and placebo, despite small earlier studies suggesting benefit.
The Dangerous Convenience of Testosterone Pellets	12:38	Observational studies report benefits beyond treating HSTD when physiological equivalence is achieved with testosterone pellets.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage addresses whether physiological doses are adequate, not the specific claim about observational studies reporting benefits beyond HSTD at physiological equivalence.
The Dangerous Convenience of Testosterone Pellets	12:47	The Davis randomized controlled trial from 1995 showed significant improvements in sexual desire and orgasm when testosterone was added to estradiol implants.	The passages confirm significant improvements in orgasm but do not mention sexual desire; the claim overstates by including desire as an outcome of the trial.
The Dangerous Convenience of Testosterone Pellets	13:04	Women using testosterone pellets reported vastly improved mood and energy.	While some observational studies note improvements in mood and energy, the claim of 'vastly improved' is stronger than the cautious language in the literature, which highlights uncontrolled designs and potential bias.
The Dangerous Convenience of Testosterone Pellets	13:10	Observational cohorts report reductions in debilitating fatigue with testosterone pellet therapy.	Observational cohorts report improvements in fatigue/energy, but the added descriptor 'debilitating' is not supported by the referenced literature.
The Female Testosterone Pellet Paradox	5:58	Observational data from practice-based registries claims benefits extending beyond sexual health, including improved mood, energy, and increased lean muscle mass.	The podcast presents observational registry findings as established benefits, but the cited passage explicitly warns that such data are low-level, hypothesis-generating, and not confirmatory, making the claim overstated.
The Hidden Androgens Your Blood Test Misses	3:53	Applying topical testosterone ointment to the affected skin of those rats regenerated the skin.	The study shows amelioration and protection, not skin regeneration; the claim inflates the findings.
The Hidden Androgens Your Blood Test Misses	5:39	Targeted localized androgen therapies could be used to repair the physical and immunological skin barrier in eczema.	The study demonstrates that topical testosterone can improve the physical skin barrier in rats, but it does not provide evidence for repairing the immunological barrier, so the claim overstates the findings.
The Hidden Androgens Your Blood Test Misses	19:04	Testosterone can fix skin barriers and cure severe eczema in rats.	The study shows topical testosterone reduced dermatitis severity in a rat model, not that it 'cures' severe eczema or acts as a 'master architect fixing skin barriers'.
The Risks of Female Testosterone Pellets	6:23	Testosterone pellets are highly effective for hypoactive sexual desire disorder (HSDD).	The claim overstates the effectiveness for pellets specifically, as the evidence is limited to one small randomized trial and mostly observational data.
Unpacking Female Desire_ The Surprising Truth About Estradiol and Testosterone	11:18	Studies that produced periovulatory levels of estradiol consistently showed a clear and significant increase in sexual desire.	The passage describes a natural association between ovulation and increased sexual desire, but it does not demonstrate that studies producing periovulatory estradiol levels consistently found a clear and significant increase as claimed.
Unpacking Female Desire_ The Surprising Truth About Estradiol and Testosterone	12:10	Estradiol significantly increases vaginal lubrication, which reduces painful intercourse (dyspareunia).	The claim asserts a significant increase in lubrication directly reducing dyspareunia, but the passage only suggests a tendency for estrogen therapy to help with vaginal dryness and painful intercourse, a weaker statement.
What testosterone does to your brain	12:58	In the 2025 study, crying spells, profound exhaustion, and inability to concentrate drastically improved.	The study found statistically significant but modest improvements, not 'drastic' ones, and the observational design precludes causal conclusions.
What testosterone does to your brain	17:36	Testosterone aids specific memory domains and treatment-resistant depression in hypogonadal men.	The study reports significant improvements, but the evidence certainty is moderate and the paper calls for larger trials; claiming it 'clearly aids' overstates the strength of the evidence.
What testosterone does to your brain	17:43	Observational data shows a spectacular mood and motivation boost from hormone therapy in women.	VERDICT UNDER REVIEW. The passage retrieved for this claim does not appear to be about it. The passage discusses RCT evidence on testosterone for menopausal symptoms, not observational data on mood and motivation boost from hormone therapy.
Why Hormone Therapy Stops Midlife Suicide	14:15	Transdermal estradiol, delivered via patches or gels, is highly effective.	The passage supports transdermal estradiol's effectiveness for PMDD but notes low-quality evidence, while the podcast presents it as highly effective without qualification, overstating the confidence.
Why Hormone Therapy Stops Midlife Suicide	14:45	The largest clinical improvements came from combined therapies of estrogen, progesterone, and testosterone, not estrogen alone.	The passage shows greater improvement with combined estrogen and testosterone, but the podcast adds progesterone to the combination, which the passage does not support.
Why Testosterone Lab Results Are Unreliable	8:56	Mass spectrometry completely eliminates the cross-reactivity problem.	The passage describes negligible cross-reactivity in one specific assay, not a complete elimination across all mass spectrometry applications.
Why Testosterone Needs Estrogen to Burn Fat	8:02	Genetically engineered mice overexpressing androgen receptor in skeletal muscle had a 14% increase in muscle mass without exercise.	The podcast claims a general increase in mice, but the study found the 14% gain only in males and limited to specific muscles (TA and EDL).
Why Testosterone Needs Estrogen to Burn Fat	15:43	Exogenous testosterone heavily impacts female muscle performance.	The passage shows exogenous testosterone increases muscle protein synthesis in postmenopausal women, but not a heavy impact on overall female muscle performance as claimed.
Why Your Hormone Blood Tests Lie	9:09	Fixing insulin resistance and lipotoxicity may require lifestyle changes or metformin to restore hair growth.	The podcast suggests metformin or lifestyle changes can restore hair growth, but the study notes metformin has only a limited direct effect and works by boosting other hair therapies.
Why Your Hormone Blood Tests Lie	12:23	Treatment with steroidogenesis inhibitors causes stealth steroids to plummet and severe clinical symptoms to improve.	The paper confirms that steroidogenesis inhibitors lower 11-oxygenated androgens, but it does not show that severe clinical symptoms improved; in fact, it found no correlation between these androgens and hyperandrogenism symptoms.
Why Your Hormone Blood Tests Lie	16:36	Topical testosterone ointment completely prevented atopic dermatitis lesions in KFRS4 rats.	Testosterone prevented lesions only in the treated area, not completely across all body regions as claimed.
Why Your Hormone Blood Tests Lie	17:34	Localized testosterone silenced Th2 and Th17 cytokine alarms, stopping allergic inflammation.	The study shows testosterone decreased Th2/Th17 cytokine gene expression in a rat dermatitis model, but the claim that it 'silenced' them and 'stopped allergic inflammation dead in its tracks' overstates the findings, which are limited to gene expression changes and do not demonstrate complete cessation of inflammation.
Why testosterone delivery is the drug	11:02	Jatenzo demonstrated highly effective improvements in psychosexual function and statistically significant increases in bone mineral density.	The podcast describes psychosexual improvements as 'highly effective,' but the paper only states they were 'clinically meaningful,' which inflates the strength of the claim.
Why total testosterone is a meaningless metric	1:58	Testosterone might act as a secret healing agent for severe skin conditions.	While one study shows topical testosterone ameliorates atopic dermatitis in rats, other evidence demonstrates it impairs wound healing, so calling it a general 'healing agent' is too broad.
Why total testosterone is a meaningless metric	13:43	The Nowotny study proved that a massive spike in 11-oxygenated androgens causes the hyperandrogenic symptoms in Cushing's disease.	The study found no significant correlation between 11-oxygenated androgens and hyperandrogenic symptoms, contradicting the claim that it proved causation; the authors only speculated about a possible role.
Why total testosterone is a meaningless metric	17:35	Orchiectomy worsened dermatitis in male KFRS4 rats, with severe crusting, erosion, and lesions matching female severity.	The study confirms orchiectomy worsened dermatitis in males, but does not state that lesions matched female severity; that is an overstatement.
Why total testosterone is a meaningless metric	18:15	Topical testosterone ointment prevented new lesions and rapidly healed existing severe dermatitis in female and orchiectomized male KFRS4 rats.	The study shows testosterone prevented lesions and reduced severity scores, but does not mention rapid healing of existing severe dermatitis; the claim overstates the findings by asserting rapid healing of severe lesions.
Why women have more testosterone than estrogen	4:45	The clinical data supporting testosterone therapy for HSDD is robust.	The claim exaggerates the strength of evidence; authoritative guidelines describe it as moderate, not robust.
Why women have more testosterone than estrogen	5:08	The study measured a marked decrease in personal distress related to sex.	The podcast claims a 'marked decrease', but the passage describes a gradual decline over months, which is less definitive than 'marked'.
Why women have more testosterone than estrogen	5:19	The testosterone patch resolved both sexually satisfying events and personal distress with minimal side effects.	The patch improved but did not resolve sexual events and distress, and side effects were not minimal; the claim overstates the benefit and understates the risks.
Why women have zero testosterone options	9:28	Testosterone counters increased beta-amyloid deposition, decreased brain cell glucose metabolism, and reduced blood flow associated with Alzheimer's disease.	The passage associates testosterone with slower decline in glucose metabolism but does not show it counters beta-amyloid or blood flow, and the claim presents the relationship as stronger than the evidence supports.
Why women need testosterone after menopause	20:13	There is overwhelming clinical evidence of systemic testosterone's efficacy for hypoactive sexual desire disorder (HSDD).	The guideline describes the evidence as moderate, not overwhelming.

How it works (48)

Episode	At	Claim	Why it overshoots
Hormones Not Antidepressants For Menopausal Moods	4:45	17-beta-estradiol, progesterone, and testosterone are potent neurosteroids.	Only progesterone is explicitly called a neurosteroid in the provided passages; the claim includes 17-beta-estradiol and testosterone without support.
Hormones Not Antidepressants For Menopausal Moods	5:33	Natural progesterone acts on the brain's GABA receptors.	The claim overstates because it is not progesterone itself but its metabolite allopregnanolone that acts on GABA receptors.
Hormones Not Antidepressants For Menopausal Moods	6:02	The neuroprotective and psychoprotective structural support is pulled away when hormones drop.	The passage supports that hormone loss reduces neuroprotective structural support, but describes a gradual weakening, not the abrupt removal implied by 'pulled right away'.
How Fat Turns Testosterone Into Estrogen	19:18	Obesity causes testosterone levels to drop, and low testosterone actively promotes fat accumulation and insulin resistance.	The podcast presents a simple cause-effect chain, but the evidence shows a bidirectional relationship where obesity and low testosterone mutually reinforce each other, not a one-way causation.
How Fat Turns Testosterone Into Estrogen	19:39	As body weight increases, testosterone decreases, and lower testosterone makes further fat gain easier.	The podcast presents a definitive causal cycle, but the passages only demonstrate associations and partial support for each direction, not the integrated feedback loop as stated.
How Testosterone Protects Women From Alzheimer's	15:56	The APOE4 gene drastically increases baseline neuroinflammation.	VERDICT UNDER REVIEW. The passage retrieved for this claim does not appear to be about it. The passage mentions higher neuroinflammation in older adults but does not reference the APOE4 gene, so it is unrelated to the claim.
How Testosterone Shapes Female Biology	6:57	Estradiol directs the body to store fat subcutaneously on the hips and thighs.	The passages show estrogen is associated with gynoid fat accumulation, but they do not state that estradiol explicitly directs subcutaneous fat storage, making the claim overstated.
How Testosterone Shapes Female Biology	9:29	The pubertal divergence in athletic performance is directly driven by the male-specific surge in circulating testosterone.	The passage shows a temporal overlap between testosterone increase and performance divergence, but does not establish direct causation, so the claim overstates the evidence.
Menopausal Depression and Immune Imbalance	5:15	E2 directly helps lower IL-6 levels in the blood.	The passage suggests estrogen can attenuate pro-inflammatory factors, but it does not directly show that E2 lowers IL-6 levels in the blood; the claim overstates the evidence by presenting a mechanistic implication as a confirmed direct effect.
Menopausal Depression and Immune Imbalance	8:47	Overactive NF-κB in microglia pushes them to a pro-inflammatory M1 phenotype, releasing TNF-α, IL-1, IL-6, which is linked to cognitive problems and depressive symptoms.	The passages support the NF-κB to M1 to cytokine to depressive behavior link, but cognitive problems are not mentioned, making the claim stronger than the provided evidence.
Precision Hormones and Nanotechnology for Depression	10:47	Testosterone regulates dopamine, drives motivation, and sharpens mental acuity.	While the passage supports testosterone's role in dopamine and motivation, the cognitive benefits are qualified as mainly in aging men, so the unqualified claim of sharpening mental acuity is overstated.
Progesterone Acts as Literal Brain Armor	10:00	A sudden drop in natural progesterone causes PND (postnatal depression).	The passage says the drop likely contributes rather than causes PND, and the exact cause is unknown, so the claim of a direct cause overstates the evidence.
Progesterone Acts as Literal Brain Armor	14:07	Progesterone and allopregnanolone act as physical armor for brain tissue, protecting it.	The passages describe biochemical neuroprotective effects, not a physical armor-like barrier, and aloe is not mentioned in any passage.
Progesterone Acts as Literal Brain Armor	18:48	Progesterone is the hidden mechanistic driver behind PMDD and postpartum depression.	Progesterone is involved in mood disorder vulnerability, but the claim inflates its role to a singular hidden driver, ignoring the complex interplay of multiple hormones and individual susceptibility described in the literature.
Testosterone Regulates Memory and Mood	7:52	Androgen deprivation therapy eliminates all testosterone in the body to starve prostate cancer cells.	ADT lowers testosterone to castrate levels, which are extremely low but not zero, so the claim of eliminating 'all' testosterone overstates the effect.
Testosterone Regulates Memory and Mood	22:11	Testosterone is the biological fuel that feeds prostate cancer.	While androgens like testosterone play a role in prostate cancer progression, describing it as the 'exact biological fuel' ignores other driving factors and the complexity of the disease, as evidenced by the development of resistance to hormone therapy.
Testosterone Therapy for Women's Desire and Mood	6:10	Only about 50% of circulating testosterone comes directly from the ovaries and adrenal glands.	VERDICT UNDER REVIEW. On a second reading the passage appears to support this claim as stated, so the verdict itself is in question. The passage indicates 25% from ovaries and 25% from adrenal glands, totaling 50% directly, which directly supports the claim.
Testosterone for Women	9:33	Low testosterone can contribute to depression, anxiety, low self-esteem, and relationship problems.	The passage supports a link between low testosterone and depression, but does not mention anxiety, low self-esteem, or relationship problems, so the podcast claim overstates the evidence.
Testosterone is the primary female hormone	4:39	Testosterone pellets cause an immediate massive initial spike in testosterone levels before tapering to a sustained plateau.	The peak occurs at about one month, not immediately, so the claim exaggerates the timing.
Testosterone rebuilds skin to silence eczema	10:54	Testosterone triggered a massive increase in the number of sebaceous glands.	The study shows a significant but not necessarily massive increase in sebaceous gland count in rats, so the podcast exaggerates the effect.
Testosterone rebuilds skin to silence eczema	11:39	The researchers observed a massive multiplication of androgen receptor‑positive cells across all layers of the treated skin.	The study reports robust induction of AR-positive cells, not a massive multiplication.
Testosterone rebuilds skin to silence eczema	12:18	Applying the testosterone ointment forced the skin to rapidly manufacture new androgen receptors.	The study shows increased androgen receptor gene expression but does not demonstrate rapid manufacturing, making the podcast claim stronger than the evidence.
Testosterone rebuilds skin to silence eczema	14:40	Overactive Th2 and Th17 pathways drive chronic inflammation, heat, swelling, and itch in severe eczema.	The passage supports Th2 cytokine involvement in eczema inflammation and itch, but does not mention Th17 pathways or symptoms of heat and swelling, making the claim overstated.
Testosterone rebuilds skin to silence eczema	15:24	IL‑5 recruits eosinophils.	The passage attributes eosinophil recruitment to IL-17A, not IL-5, which instead induces proliferation and differentiation.
Testosterone rebuilds skin to silence eczema	18:53	Activating the androgen receptor in the skin triggers a dual healing cascade that boosts filaggrin and calms the Th2 immune response.	A single rat study found that topical testosterone, which activates androgen receptors, boosted filaggrin and reduced Th2 cytokines, but claiming it as a dual healing cascade in skin overstates the evidence.
Testosterone rebuilds skin to silence eczema	20:07	In a patient with a degraded skin barrier, the root cause is often a deeply systemic hormonal imbalance, not just external factors like cold weather or harsh soap.	The passage links hormonal changes in menopause to skin barrier degradation, but the claim generalizes this to all patients with degraded skin barrier, overstating the evidence.
Testosterone rebuilds skin to silence eczema	20:54	Chronic stress, poor sleep, highly processed diets, and lack of resistance training naturally and significantly crash endogenous hormone levels daily.	The passage shows these factors can influence hormone levels (e.g., stress inhibiting GnRH/LH, sleep disorders linked to luteal deficiency, diet affecting hormonal balance), but it does not state they 'naturally and significantly crash endogenous hormone levels every single day' with the absolute, daily, and dramatic certainty claimed.
Testosterone therapy for female sexual desire	3:36	After bilateral oophorectomy, testosterone levels can drop by up to 50% overnight.	The cited study shows a 40-50% lower level compared to controls, not a 50% abrupt overnight drop; the podcast presents this as an acute overnight change, whereas the data reflects a chronic difference relative to naturally menopausal women.
Testosterone, GABA, and Depression in Women	11:46	Testosterone might influence activity in the posterior cingulate cortex, impacting depressive symptoms like rumination, possibly by dampening excessive activity via GABA.	The study found a baseline correlation but no causal effect of testosterone on PCC activity, and it did not address rumination or GABA.
The Hidden Androgens Your Blood Test Misses	7:42	The root cause of hair follicle miniaturization in PCOS is a profound local metabolic failure driven by insulin resistance, hyperinsulinemia, and lipotoxicity.	The review presents a multifactorial model where metabolic failure and genetics interact, and androgens are necessary but not sufficient; the podcast simplifies this to a single root cause of local metabolic failure, overstating the case.
The Hidden Androgens Your Blood Test Misses	9:31	Insulin resistance-induced metabolic stress and inflammation make hair follicles vulnerable to miniaturization by androgens.	The passages show insulin resistance contributes to miniaturization and amplifies androgen effects, but they do not state that androgens would not cause miniaturization without insulin resistance, making the claim stronger than the evidence.
The Hidden Androgens Your Blood Test Misses	9:42	The metabolic stress creates the vulnerability, and the androgens merely amplify the damage.	The podcast claims androgens merely amplify damage, but the passage indicates androgens also directly promote pathological changes, making the claim stronger than the evidence.
The Hidden Androgens Your Blood Test Misses	12:00	11-ketotestosterone (11-KT) and 11-OHA4 are androgens structurally different from testosterone but functionally highly potent.	The paper shows 11-KT has potency equal to testosterone, but does not provide evidence that 11-OHA4 is also highly potent; the claim overstates by including 11-OHA4 as incredibly potent without support.
The Hidden Androgens Your Blood Test Misses	12:36	11KT binds to the androgen receptor with the same affinity and potency as classical testosterone.	The study describes affinity as comparable, not identical, and does not claim exact same potency, making the podcast's assertion of exact same affinity and potency an overstatement.
The Hidden Androgens Your Blood Test Misses	14:05	11-oxygenated androgens are produced exclusively by the adrenal glands, not the ovaries, based on selective venous sampling.	The podcast claims definitive proof of exclusive adrenal production, but the study itself states that the biosynthesis debate persists, and it does not establish absolute exclusivity.
The Hidden Androgens Your Blood Test Misses	17:54	In cultured muscle cells from the same women, testosterone-induced growth was driven strictly by androgen receptor nuclear translocation.	The study found growth alongside AR nuclear translocation and no mTOR activation, but it did not demonstrate that AR translocation strictly drives the growth, making the claim stronger than the evidence.
The Hidden Androgens Your Blood Test Misses	18:25	Selective deletion of the androgen receptor from osteoblasts in mice caused significant bone loss.	The animal data indicate bone changes that are described as minor and bone-dependent, with one model showing no change in bone mineral density, so the claim of significant bone loss is stronger than the evidence supports.
The Hidden Androgens Your Blood Test Misses	19:17	Androgens do not destroy healthy hair follicles on their own; insulin resistance dictates hair loss.	The passages show androgens directly cause hair follicle miniaturization, while insulin resistance is only a contributing factor, not the sole dictator of hair loss.
The Risks of Female Testosterone Pellets	19:45	Genetically higher testosterone drives visceral fat and diabetes in women.	VERDICT UNDER REVIEW. On a second reading the passage appears to support this claim as stated, so the verdict itself is in question. The passage states that androgen excess (including testosterone) drives adipose dysfunction and metabolic deterioration in women, directly supporting the claim.
What testosterone does to your brain	10:17	Testosterone restores network efficiency and neuroplastic resilience only when there is a documented deficit.	The podcast claims testosterone definitively restores network efficiency and neuroplastic resilience, but the cited study only suggests it 'maybe' does so, indicating the claim is stronger than the evidence.
Why Hormone Therapy Stops Midlife Suicide	0:46	The data strongly indicates that perimenopausal distress is a biological hormone crisis, not a standard psychiatric disorder.	No passage states that perimenopausal distress is a biological hormone crisis and not a psychiatric disorder. Instead, they describe perimenopausal depression as involving a complex interplay of biological, psychological, and social factors, and hormone sensitivity as a risk factor for psychopathology. Thus, the claim is overstated by presenting a complex issue as a simple, strongly indicated fact.
Why Hormone Therapy Stops Midlife Suicide	4:45	The perimenopausal subtype of depression is driven by a severe deficit of estradiol, not by serotonin depletion.	The passage indicates that estrogen deficit triggers serotonin depletion, which then contributes to depression, contradicting the claim that serotonin depletion is not involved.
Why Hormone Therapy Stops Midlife Suicide	5:59	Loss of neuroprotective scaffolding and GABA modulation leads to severe mood volatility, heart palpitations, chronic insomnia, and intense anxiety.	While GABA modulation influences mood and anxiety, the passages do not support that its loss directly causes heart palpitations, chronic insomnia, or severe mood volatility, nor do they mention 'neuroprotective scaffolding'.
Why total testosterone is a meaningless metric	5:52	If androgen receptors do not move into the nucleus, muscle does not grow regardless of how much testosterone is outside the cell.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage describes the translocation of androgen receptors upon ligand binding but does not address the claim about muscle growth or the effect of receptor non-translocation.
Why total testosterone is a meaningless metric	10:05	Reducing aromatase activity shifts the local balance in the scalp toward androgen dominance.	The source shows reduced aromatase shifts hormonal balance toward androgen dominance and increases risk of androgenetic alopecia, but does not specifically mention 'local balance in the scalp' or 'heavily'.
Why total testosterone is a meaningless metric	15:27	11-oxygenated androgens are strictly produced by the adrenal glands.	The claim of strict adrenal production is overstated because the literature shows that while the key enzyme is adrenal-specific, there is conflicting in-vitro evidence of gonadal production and no definitive in-vivo proof of exclusivity.
Why women have zero testosterone options	6:38	Bilateral oophorectomy also causes a drastic drop in testosterone, which receives almost zero clinical attention.	The testosterone drop is real, but clinical attention is not near zero, as testosterone replacement therapy is considered for these women.
Why women have zero testosterone options	17:15	If left unchecked, hyperplasia can mutate into adenocarcinoma.	The claim that hyperplasia can mutate into adenocarcinoma is true only for atypical hyperplasia/EIN, not all hyperplasia, and the podcast's phrasing implies a certainty and inevitability not supported by the cited progression risks.

What guidelines say (39)

Episode	At	Claim	Why it overshoots
Hormone therapy reduces mortality after sixty-five	15:22	Non-oral therapy is supported by the highest level of observational data for persistent symptoms and long-term preventative benefits.	The study explicitly states that observational data is not high-level evidence, while the podcast claims it is the highest level of observational data.
How Fat Turns Testosterone Into Estrogen	12:29	The LC-MSMS blood test (morning fasting) is necessary for diagnosing LOH.	The passage supports morning fasting blood testing for diagnosing male hypogonadism, but does not state that LC-MSMS specifically is necessary, making the claim stronger than the evidence.
How Fat Turns Testosterone Into Estrogen	13:09	Blood for testosterone testing must be drawn in the morning, ideally between 7:00 and 11:00.	The guideline recommends morning draw between 7 and 10 a.m., not up to 11 a.m., and uses 'should' rather than 'must'.
How Fat Turns Testosterone Into Estrogen	16:17	Free testosterone test serves as a critical tiebreaker for men in the gray zone.	The claim that free testosterone test serves as a critical tiebreaker for men in the gray zone is based on conjecture, supported only by a study where free testosterone changes were not statistically significant, and no evidence is provided on how it resolves gray zone diagnoses.
How muscle strength saves your brain	11:05	The only evidence-based first-line treatment for sarcopenia is progressive resistance-based physical activity.	The passage supports PRT as a primary treatment but does not establish it as the only evidence-based first-line treatment; the claim overstates the exclusivity.
How muscle strength saves your brain	19:10	To avoid disability, one must monitor grip strength and the ability to stand from a chair unassisted.	The passage indicates these tests are informative for functional assessment, but does not support the claim that monitoring them is necessary to avoid disability; the podcast inflates the certainty.
Menopause Does Not Crash Your Testosterone	1:10	There is a widespread practice of prescribing testosterone to alleviate menopause symptoms.	Testosterone is used in specific menopause contexts like surgical menopause, but the claim of a widespread, huge cultural wave is exaggerated given the lack of approved products and reliance on off-label compounding.
Precision Hormones and Nanotechnology for Depression	2:27	Clinical guidelines argue that perimenopausal depression is a completely distinct subtype of major depressive disorder.	The passage says menopausal depression differs from typical MDD, but does not claim it is a 'completely distinct subtype' as stated in the podcast; the claim overstates the distinction.
Testosterone Regulates Memory and Mood	19:39	Monitoring hematocrit is vital to prevent cardiovascular danger.	The passage recommends hematocrit monitoring and links rising levels to cardiopulmonary review, but does not state it is 'vital' to prevent cardiovascular danger, making the podcast claim stronger than the evidence.
Testosterone Regulates Memory and Mood	21:28	Multidisciplinary care is essential for patients on hormone-altering therapies.	The passage shows multidisciplinary care is essential for testosterone replacement in male hypogonadism, but the podcast overstates this by applying it to all hormone-altering therapies.
Testosterone Regulates Memory and Mood	21:34	Routine cognitive monitoring is needed alongside physical scans.	The study supports routine cognitive monitoring for prostate cancer patients on ADT, but it does not mention physical scans or specify that cognitive monitoring must be conducted alongside them.
Testosterone Therapy for Women's Desire and Mood	8:34	HSDD diagnosis must remain a purely clinical symptom-based assessment.	While clinical assessment is key and testosterone levels are not diagnostic, lab tests are still recommended to identify contributing factors, so the diagnosis is not purely symptom-based.
Testosterone Therapy for Women's Desire and Mood	21:05	Scrupulously physiological dosing is absolutely necessary in HSDD treatment to avoid irreversible masculinizing changes.	While the passages recommend physiological dosing to maintain safety, they do not claim that non-physiological dosing necessarily causes irreversible masculinizing changes, so the statement overstates the evidence.
Testosterone Therapy for Women's Desire and Mood	23:34	Non-oral transdermal preparations (patches, gels, creams) are strongly recommended as the most physiological form of replacement therapy.	The podcast claims a strong, unified recommendation for transdermal as the most physiological, but the cited literature presents it merely as an appealing alternative for some, not a universal strong recommendation.
Testosterone Therapy for Women's Desire and Mood	27:46	If testosterone levels exceed the upper limit of the physiological range, the dose must be decreased immediately, even without overt side effects, to prevent irreversible masculinization.	The passages support reducing the dose when levels are supraphysiologic even without symptoms, but they do not state it must be done immediately or that it prevents irreversible masculinization.
Testosterone Therapy for Women's Desire and Mood	31:15	Oral testosterone formulations must be avoided because they cause adverse lipid shifts and decrease HDL cholesterol.	While oral testosterone does cause adverse lipid changes including decreased HDL, the primary reason for avoidance in the literature is hepatic toxicity, not solely lipid shifts, making the claim overstated.
Testosterone Therapy for Women's Desire and Mood	32:56	Clinicians should cautiously administer testosterone using off-label non-oral products at about one-tenth the male dose, with meticulous monitoring and informed consent regarding unproven long-term breast cancer risk beyond 24 months.	The passages support off-label use, one-tenth dosing, monitoring, and informed consent, but they do not specifically mention unproven long-term breast cancer risk beyond 24 months, making the claim more specific than the evidence.
Testosterone for female sexual desire	10:18	This is a safe, effective, guideline-backed therapy for healthy post-menopausal women in the short term.	The claim that menopausal hormone therapy is categorically safe is overstated because this passage links even short-term use to increased dementia risk.
Testosterone for female sexual desire	14:57	ISSWSH guidelines do not recommend testosterone therapy for premenopausal women.	The ISSWSH guidelines highlight limited evidence and call for more research, not an explicit recommendation against testosterone therapy in premenopausal women.
Testosterone for female sexual desire	21:47	For postmenopausal HSDD, testosterone therapy is highly effective, guideline-backed, and powerful.	The podcast describes testosterone therapy as 'highly effective,' but the supporting evidence reports only a 'moderate therapeutic benefit,' overstating the actual effect.
Testosterone is the primary female hormone	2:07	For HSDD, guidelines only recommend transdermal applications, not pellets.	Guidelines do not explicitly restrict to transdermal only; they state implants are not recommended but do not say transdermal is the only officially approved route.
Testosterone therapy for female sexual desire	7:23	Before prescribing off-label testosterone, a physician must evaluate biological, psychological, and social factors.	The guideline advises ruling out psychological/social contributors, but the claim inflates this into a mandatory comprehensive biopsychosocial evaluation.
Testosterone therapy for female sexual desire	9:58	Guidelines instruct women to measure out exactly four drops of gel.	The guideline says 'approximately 4 drops/day,' not an exact count, so the claim overstates the precision.
Testosterone therapy for female sexual desire	10:13	The gel must be applied to the lower abdomen or upper thigh and allowed to dry completely.	The passages recommend the upper outer thigh as one of several application sites, but do not mention the lower abdomen or the need to let the gel dry completely, making the podcast's directive overly specific and partially unsupported.
Testosterone therapy for female sexual desire	18:06	The goal of testosterone level monitoring is purely safety, not to chase a specific number for HSDD cure.	The monitoring goal is safety and not chasing a specific number, but the measurement also has a diagnostic exclusion purpose, so it is not purely safety.
Testosterone therapy for female sexual desire	18:51	The recommended approach is off-label, heavily monitored, down-titrated pharmaceutical transdermal gels.	The passages support off-label use of pharmaceutical gels with monitoring, but the specific recommendation of 'down-titrated' dosing overstates the guidance, which simply advises dosing appropriate for women without specifying a down-titration protocol.
The Dangerous Convenience of Testosterone Pellets	9:27	Subcutaneous testosterone pellets are being used extensively off-label for women.	The passages confirm off-label use but describe it as occasional, not extensive, so the claim overstates the frequency.
The Female Testosterone Pellet Paradox	1:14	Official guidelines mandate the use of transdermal patches or daily gels for HSDD and emphasize strict biochemical safety margins.	The guidelines favor transdermal patches and gels but do not mandate them, and the emphasis on strict biochemical safety margins is attributed to regulators, not the guidelines themselves.
The Female Testosterone Pellet Paradox	16:41	Patients require regular LC-MSMS blood draws to check total testosterone levels.	Regular monitoring of total testosterone is advised, but the specific requirement for LC-MSMS is not supported by these passages.
The Female Testosterone Pellet Paradox	17:22	Liver enzymes must be tracked closely to ensure metabolic pathways aren't overly stressed.	While monitoring liver enzymes is recommended in specific clinical contexts, the claim that it ensures metabolic pathways aren't overly stressed is an overstatement not supported by the passages.
The Female Testosterone Pellet Paradox	17:40	Regulatory guidelines demand a strict 55 nanogram ceiling for testosterone levels.	The passage describes 55 ng/dL as the upper typical range, with variability, not a strict regulatory ceiling.
Why Hormone Therapy Stops Midlife Suicide	7:57	Clinical guidelines historically recommend SSRIs and psychological therapy for midlife depression, citing a lack of formal clinical trial evidence for hormone therapy.	Guidelines do recommend SSRIs and psychotherapy, but the claim that they specifically cite a lack of formal clinical trial evidence for hormone therapy is not supported in the provided passages.
Why Your Hormone Blood Tests Lie	14:46	The ratio of testosterone to 11-KT can replace suppression tests and expensive imaging for diagnosing source of androgen excess.	The paper proposes the ratio as a potential aid, but it does not claim it can replace suppression tests and imaging; it calls for larger studies, so the podcast's claim overstates the strength of the evidence.
Why women have zero testosterone options	15:03	Compounding pharmacies are held to strict standards for testing purity, potency, and sterility under CGMP.	The podcast claims compounding pharmacies are subject to strict CGMP testing, but the passage states they are exempt from CGMP requirements, so the claim overstates the regulatory oversight. VERDICT UNDER REVIEW: the passage contradicts the claim outright rather than merely overstating it, so OVERSTATED may be too weak.
Why women have zero testosterone options	16:57	When prescribing estrogen to a woman with a uterus, physicians must simultaneously prescribe progesterone to protect the uterine lining.	While progesterone is necessary to protect the uterine lining, it is not always started simultaneously with estrogen; in some cases, such as pubertal induction, it may be deferred to allow uterine development.
Why women have zero testosterone options	21:11	Major society consensus statements consistently proclaim that bioidentical hormones shouldn't be used.	The claim says consensus statements 'proclaim that bioidentical hormones shouldn't be used,' but the passage shows major societies only discourage compounded bioidentical hormones, not all bioidentical hormones, and even then only outside clinical trials.
Why women need testosterone after menopause	9:34	The Endocrine Society strictly recommends against diagnosing female androgen deficiency based on blood work.	The guideline states that no blood level cutoff can be used for diagnosis, but it is a weak recommendation (Grade C) based on low-quality evidence, so 'strictly recommends' overstates the strength of the recommendation.
Why women need testosterone after menopause	16:51	Before prescribing testosterone, physicians are required to conduct a thorough psychosocial assessment.	The podcast claims a required thorough psychosocial assessment, but the guideline only recommends a biopsychosocial assessment, overstating both the strength and specificity.
Why women need testosterone after menopause	19:06	The FDA has approved intravaginal DHEA (Prastrone) for genitourinary syndrome of menopause (GSM).	The FDA approval is for dyspareunia, a symptom of GSM, not for the full genitourinary syndrome of menopause.

Safety and risk (35)

Episode	At	Claim	Why it overshoots
Hormone Therapy and Endometrial Health in Postmenopausal Women	15:29	Studies documented an increased risk of endometrial cancer among users of micronized progesterone, even when given continuously.	The passage says risk 'may' be increased, whereas the claim asserts studies have documented an increased risk, which is a stronger statement than the evidence supports.
Hormones Not Antidepressants For Menopausal Moods	4:11	Antidepressants come with risks and side effects like blunted affect, sexual dysfunction, and bone density issues over the long term.	The passage supports sexual dysfunction but not blunted affect or bone density, making the podcast claim overly broad.
Precision Hormones and Nanotechnology for Depression	6:54	The stroke risk in the WHI study was caused by oral hormones passing through the liver and triggering clotting factors.	VERDICT UNDER REVIEW. On a second reading the passage appears to support this claim as stated, so the verdict itself is in question. The passage directly states that oral estrogens increase clotting factors via hepatic metabolism, which matches the claim's mechanism for stroke risk.
Precision Hormones and Nanotechnology for Depression	7:07	Body-identical transdermal estradiol and micronized progesterone bypass the liver and are incredibly safe.	The passages show that body-identical hormones are considered safer than synthetic alternatives for some risks, but they do not support the claim that they are 'incredibly safe,' and the assertion about liver bypass is not addressed.
Testosterone Regulates Memory and Mood	9:39	Androgen deprivation therapy (ADT) increases fat mass.	The passage supports increased fat mass and some cardiovascular and bone density changes, but describes bone loss as 2-8%, not 'massive', and does not mention sexual dysfunction at all, making the claim overstated.
Testosterone Regulates Memory and Mood	9:39	Androgen deprivation therapy (ADT) increases cardiovascular risk.	While the paper confirms increased cardiovascular risk and fat mass, it describes bone density loss as 2-8% and lists sexual dysfunction without severity, so the podcast's 'massive' and 'severe' descriptors are overstated.
Testosterone Regulates Memory and Mood	9:39	Androgen deprivation therapy (ADT) causes massive loss of bone density.	The claim is overstated because the passage shows bone density loss of 2-8%, not necessarily 'massive', and severe sexual dysfunction is not mentioned in the provided passages.
Testosterone Regulates Memory and Mood	17:44	Super-physiological doses of testosterone made healthy young eugonadal men modestly more aggressive and impulsive.	The study found modestly increased aggression, but did not report on impulsivity, so the claim adds an unsupported effect.
Testosterone Therapy for Women's Desire and Mood	24:00	Compounded testosterone products must be strictly avoided due to lack of safety and efficacy data and documented high variability in concentration.	The sources recommend against use rather than demanding strict avoidance, and they describe variability as possible, not documented high, making the claim stronger than the evidence.
Testosterone Therapy for Women's Desire and Mood	25:07	Oral testosterone formulations cause an adverse lipid shift by decreasing HDL cholesterol, a direct cardiovascular risk factor.	The passage mentions changes in HDL levels with oral testosterone but does not explicitly state a decrease, so the claim that it decreases HDL is overstated based on this evidence alone.
Testosterone is the primary female hormone	13:42	The most common and immediate side effects of exogenous testosterone are androgenic.	The passage confirms androgenic effects as the most common but does not describe them as immediate, making the claim stronger than the evidence.
Testosterone is the primary female hormone	18:48	Pellet variation could cause blood testosterone levels to spike to 200 or 400 ng/dL.	The passage shows pellet-induced testosterone spikes around 250 ng/dL in women, but provides no evidence for spikes reaching 400 ng/dL, overstating the claim's magnitude.
Testosterone is the primary female hormone	19:42	Testosterone pellets cause no adverse cardiovascular effects, including no spikes in heart attacks or strokes.	The claim that pellets cause absolutely no adverse cardiovascular effects overstates the evidence, which is based on studies that found no excess risk but had limited power to detect rare events.
Testosterone rebuilds skin to silence eczema	18:03	Known adverse effects of topical testosterone include severe cystic acne and localized skin redness.	The claim specifies 'severe cystic acne' and 'localized skin redness' along with a mechanism, but the passage only mentions general acne and skin redness without severity or cause.
Testosterone rebuilds skin to silence eczema	18:26	Broadly applying a potent sex hormone can trigger mood volatility, breast tenderness, and in men, significant prostate enlargement.	The passage confirms testosterone therapy can cause mood changes, breast tenderness, and prostate enlargement, but does not support the claim's stronger wording of 'significant' prostate enlargement.
Testosterone therapy for female sexual desire	10:19	They must strictly avoid skin-to-skin contact with partners or children to prevent accidental hormone transference.	The claim demands strict avoidance of all skin-to-skin contact, but the cited passage recommends caution and hand washing rather than a complete prohibition.
Testosterone therapy for female sexual desire	16:34	Severe androgenic effects like voice deepening or clitoral enlargement are exceedingly rare if dose stays within physiological limits.	The study states these effects are 'rare' at normal doses, but the podcast amplifies to 'exceedingly rare', which is a stronger claim than the evidence supports.
Testosterone therapy for female sexual desire	18:27	Oral testosterone formulations are strongly discouraged due to adverse effects on lipid profiles and liver function.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage only discusses adverse lipid profiles and does not mention liver function, so it cannot fully evaluate the claim.
The Dangerous Convenience of Testosterone Pellets	13:41	Testosterone pellets have a complete lack of reversibility.	The podcast claims a complete lack of reversibility, but the passage describes a lack of immediate reversibility, not an absolute absence of reversibility.
The Dangerous Convenience of Testosterone Pellets	16:03	Supraphysiologic testosterone peaks in women cause virilization effects.	The study found that even at supraphysiologic levels, few androgenic effects occurred, contradicting the claim that such peaks cause a whole host of virilization effects.
The Hidden Androgens Your Blood Test Misses	5:51	Applied topically, androgens could heal the skin architecture without systemic side effects.	The study shows topical testosterone can heal skin lesions in rats, but it does not assess systemic side effects, so claiming no systemic side effects is overstated.
The Risks of Female Testosterone Pellets	5:55	Removing a testosterone pellet requires surgical extraction that most doctors won't perform, leaving patients to wait months for dissolution.	The passage confirms that testosterone pellets lack immediate reversibility, requiring a wait for dissolution, but it does not mention surgical extraction or that most doctors won't perform it, making the claim stronger than the evidence.
The Risks of Female Testosterone Pellets	12:19	In a midlife woman, male-level testosterone via pellets triggers storage of visceral fat and drives diabetes.	The podcast inflates the natural androgen shift of menopause into a claim that exogenous male-level testosterone pellets directly trigger visceral fat storage and diabetes, which the passages do not support.
The Risks of Female Testosterone Pellets	15:03	In trans men, testosterone often triggers male pattern baldness.	The claim that testosterone often triggers male pattern baldness in trans men overstates the evidence; the passage shows that it depends on genetic susceptibility, not a frequent automatic effect.
Unpacking Female Desire_ The Surprising Truth About Estradiol and Testosterone	3:23	The high testosterone doses came with significant virilization including voice deepening, clitoral enlargement, and increased facial hair.	The claim presents virilization as a significant and common outcome of high testosterone doses, but the source indicates that clitoral enlargement and voice deepening are rare.
Why Hormone Therapy Stops Midlife Suicide	6:37	SSRIs often cause side effects that mimic or exacerbate the perimenopausal hormonal crash, including further weight gain, severe agitation, and blunted libido.	SSRIs can cause agitation and decreased libido, and some cause weight gain, but the claim that they often mimic or exacerbate the perimenopausal hormonal crash is not directly supported by the passages.
Why testosterone delivery is the drug	11:38	Across this entire class of oral testosterone medications, blood pressure increases and suppression of HDL cholesterol are consistently seen.	The passage supports blood pressure increases with oral testosterone but does not mention HDL cholesterol suppression, making the claim stronger than the evidence provided.
Why women have more testosterone than estrogen	6:15	Vaginal DHEA accomplishes its effects without spiking systemic hormone levels.	The claim that vaginal DHEA causes no systemic hormone spike is overstated because studies show small but measurable increases in serum estradiol and testosterone, even if within postmenopausal ranges.
Why women have zero testosterone options	3:02	In the WHI trial, those adverse events were seen in the combined estrogen plus progestin arm but not in the estrogen-only arm.	The estrogen-only arm had an increased risk of stroke, contradicting the claim that adverse events were seen only in the combined arm.
Why women have zero testosterone options	13:08	The continuation rate for women using subcutaneous pellets was 93% and the overall complication rate was less than 1%.	The passage supports a complication rate below 1% for pellets, but does not mention a 93% continuation rate, so the claim overstates the evidence.
Why women have zero testosterone options	17:09	Unopposed estrogen leads to hyperplasia, a dangerous overgrowth of cells in the uterine lining.	The podcast describes hyperplasia as a dangerous overgrowth, but the cited research shows it spans from benign to malignant, making the blanket 'dangerous' label overstated.
Why women have zero testosterone options	21:53	Testosterone has 80 years of clinical use and a mountain of data showing its safety, especially when delivered via slow-release subcutaneous pellets.	The claim overstates the strength of safety evidence; existing data are observational and not confirmatory, lacking the robust support implied by 'a mountain of data'.
Why women need testosterone after menopause	22:04	The global medical consensus is that transdermal testosterone (patches, gels, creams) is the safest and most preferred method.	The passage indicates transdermal testosterone is preferred in clinical studies for women, but it does not claim a global medical consensus that it is the safest and most preferred method for all.
Why women need testosterone after menopause	23:31	Compounded pellets and intramuscular injections are known to cause dangerous, uncontrollable spikes in hormone levels.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage addresses only intramuscular injections, not compounded pellets, so it cannot judge the full claim.
Why women need testosterone after menopause	23:47	The safest, most evidence-based path is low-dose transdermal testosterone with physician monitoring.	The claim overstates by presenting low-dose transdermal testosterone as the safest, most evidence-based path overall, while the evidence supports its use only for specific conditions like HSDD and depression, with careful monitoring.

Testing and measurement (31)

Episode	At	Claim	Why it overshoots
How muscle strength saves your brain	9:24	The most predictive tests for sarcopenia are functional: gait speed and grip strength measured with a handheld dynamometer.	The passages highlight the clinical value of grip strength and gait speed but do not support the assertion that they are the most predictive tests for sarcopenia.
Testosterone Regulates Memory and Mood	12:41	Studies using complex multi-domain neuropsychological test batteries found severe cognitive decline from ADT.	The scoping review indicates that comprehensive test batteries are more sensitive and may detect under-reported impairment, but it does not explicitly support the claim that studies using them found 'severe' cognitive decline, nor that only those batteries reveal severe decline.
Testosterone Regulates Memory and Mood	13:08	We may be systematically missing the true cognitive cost of ADT because we aren't testing for it properly.	The podcast claim that true cognitive costs are systematically missed due to improper testing is overstated because the passage emphasizes variability in study designs and assessment tools, but does not support the idea that current testing systematically misses true costs; rather, it suggests limited and domain-specific vulnerabilities.
Testosterone Therapy for Women's Desire and Mood	27:35	The target testosterone concentration during therapy is within the premenopausal physiological range, generally up to 27-57.5 ng/dL.	While therapy aims to keep testosterone in the premenopausal range, guidelines explicitly state not to dose to a specific numerical target, making the claim of a target concentration overstated.
Testosterone Therapy for Women's Desire and Mood	32:45	Testosterone levels are used only for monitoring the dose and preventing overdose, not for diagnosing HSDD; diagnosis is based purely on subjective distress.	While testosterone levels are not used to diagnose HSDD, they are also used before therapy to exclude women with high baseline levels, and diagnosis involves more than just subjective distress, including physical exam and questionnaires.
Testosterone is the primary female hormone	22:25	Doctors need to specifically check total testosterone using the ultra-precise LC-MSMS assay to ensure early spikes aren't pushing into dangerous territory.	The consensus says direct assays can be used to check for high testosterone levels during treatment, so the requirement for LC-MSMS is overstated.
Testosterone rebuilds skin to silence eczema	12:38	Filaggrin is arguably the most important structural protein in the human epidermis.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage notes filaggrin's crucial role in barrier function but does not compare it to other structural proteins or claim it is the most important.
Testosterone therapy for female sexual desire	17:35	Patients must be tested using LC-MS/MS for accurate testosterone measurement.	Guidelines allow direct assays when LC-MS/MS is unavailable, so the absolute 'must' is overstated.
Testosterone therapy for female sexual desire	17:46	LC-MS/MS eliminates cross-reactivity and provides accurate measurement at low levels.	LC-MS/MS reduces cross-reactivity to negligible levels, but the claim that it 'completely eliminates' it is an overstatement, as the passage only says it is negligible under specific conditions.
Testosterone therapy for female sexual desire	19:39	Testosterone replacement demands strict, ongoing laboratory monitoring using mass spectrometry.	While mass spectrometry is the recommended gold standard, clinical guidelines also accept immunoassays with proper calibration, so strict demand for mass spectrometry alone overstates the requirement.
The Hidden Androgens Your Blood Test Misses	10:20	A normal blood test result may be misleading.	The claim broadly asserts normal blood tests can be misleading, but the passage only supports this in the narrow context of Turner syndrome diagnosis, where a normal blood karyotype may miss mosaicism. The podcast inflates a specific exception into a general rule.
The Hidden Androgens Your Blood Test Misses	11:48	Researchers discovered a previously hidden pool of androgens called 11-oxygenated C19 steroids.	The podcast presents these steroids as a newly discovered hidden pool, but the cited paper itself references prior studies that had already measured them, indicating they were known before.
The Hidden Androgens Your Blood Test Misses	12:30	Over half of the active androgens in women with PCOS are invisible to standard diagnostic tests.	The paper says 11-oxygenated androgens are the majority of androgen excess, not that over half of active androgens are 'invisible', standard tests often measure these androgens, but they are not always included in routine panels, making the claim of complete invisibility an overstatement.
The Hidden Androgens Your Blood Test Misses	19:33	Standard blood tests cannot detect 11-oxygenated androgens, which come from the adrenal glands.	Standard clinical tests usually measure testosterone, not 11-oxygenated androgens, but these androgens are detectable in blood with specialized assays, so the claim overstates the limitation.
The Risks of Female Testosterone Pellets	5:09	Using LC-MSMS, the normal testosterone upper limit for postmenopausal women is 10-55 ng/dL.	The claim that the upper limit is 10-55 ng/dL overstates the range; the cited passage indicates the upper limit is around 50-55 ng/dL, not as low as 10.
The Risks of Female Testosterone Pellets	19:24	Monitoring hematocrit levels can help ensure bone marrow isn't dangerously thickening your blood.	The claim generalizes hematocrit monitoring as a broad health safeguard, but the supporting passage only justifies such monitoring specifically during testosterone replacement therapy, not for the general population.
Total testosterone is a biological smokescreen	10:30	A basic blood test for total testosterone does not reveal usable bioavailable testosterone.	The study shows total testosterone is not associated with muscle outcomes, but total and bioavailable testosterone are correlated (r=0.65), so the claim that the test is 'completely blind' to bioavailable testosterone is overstated.
Why Testosterone Lab Results Are Unreliable	10:51	Measuring testosterone in older men, women, and prepubescent children using immunoassay machines is virtually useless because low baseline levels cause overestimation from cross-reactivity.	The passage states immunoassays are acceptable for adult men and that a more accurate method is preferred for low levels, not that they are virtually useless, and it does not mention cross-reactivity or overestimation.
Why Your Hormone Blood Tests Lie	14:15	The ratio of standard testosterone to 11-KT in a peripheral blood draw can help determine if androgen excess is ovarian or adrenal.	VERDICT UNDER REVIEW. On a second reading the passage appears to support this claim as stated, so the verdict itself is in question. The passage directly proposes the same ratio to help distinguish adrenal from ovarian androgen excess, matching the claim.
Why Your Hormone Blood Tests Lie	14:36	High 11-OHA4 and 11-KT levels definitively point to an adrenal source of androgen excess.	The study suggests 11-OHA4 and 11-KT can help identify adrenal androgen excess, but it does not claim they 'definitively' point to an adrenal source; the podcast overstates the certainty.
Why testosterone delivery is the drug	2:56	With biweekly injections, serum testosterone peaks around days 4-5 and crashes to a sub-therapeutic trough by day 14.	The peak timing and supraphysiologic level are supported, but the passage describes the trough as 'substantially lower' rather than explicitly sub-therapeutic, so the claim overstates the trough severity.
Why testosterone delivery is the drug	5:03	When SHBG is elevated, a total testosterone reading on day 14 can appear normal while free bioavailable testosterone is low.	The passages confirm that elevated SHBG can decrease free testosterone, but they do not state that total testosterone appears normal or is a 'mirage,' which is an overstatement.
Why total testosterone is a meaningless metric	0:00	The total testosterone blood test might be a completely meaningless metric.	The study found total testosterone was not associated with muscle in premenopausal women, but calling it 'completely meaningless' overstates the evidence, as it may be relevant for other outcomes or populations.
Why total testosterone is a meaningless metric	3:27	Bioavailable testosterone and the proportion of androgen receptors localized inside the nucleus of muscle cells are what actually matter for muscle outcomes.	The paper shows an association, not that these factors definitively 'matter' as causal determinants of muscle outcomes. The claim overstates the strength of the evidence.
Why total testosterone is a meaningless metric	13:02	Mass spectrometry finally revealed that 11-oxygenated hormones were flooding the system.	The study shows that 11-oxygenated androgens are the predominant androgens in PCOS, but does not use language like 'flooding the system,' which overstates the quantitative finding.
Why total testosterone is a meaningless metric	21:04	The era of looking at a single number on a systemic blood test to diagnose complex metabolic and cellular issues is rapidly coming to an end.	The podcast declares a definitive end to single-test diagnosis, but the passage only suggests it as a beneficial consideration in a specific clinical context (pre-HRT), using tentative language.
Why women have more testosterone than estrogen	15:26	Standard testosterone assays are highly inaccurate at the lower ranges typical for women and practically useless for guiding therapy.	Some immunoassays show significant bias at low testosterone levels, but others perform within acceptable limits, so the claim that all standard assays are highly inaccurate and useless is overstated.
Why women need testosterone after menopause	7:47	Obesity and insulin use decrease SHBG, increasing free testosterone; pregnancy, hyperthyroidism, and exogenous estrogen therapy increase SHBG, decreasing free testosterone.	While obesity, insulin, hyperthyroidism, and estrogen are supported by the passages, pregnancy is not mentioned as a factor affecting SHBG, making the claim overstated.
Why women need testosterone after menopause	9:02	Older direct radioimmunoassays are essentially useless for measuring female testosterone levels.	While direct assays are highly unreliable, the passage notes they still have appropriate clinical uses, so calling them 'essentially useless' overstates the case.
Why women need testosterone after menopause	16:12	Clinically significant personal distress is the defining factor of HSDD.	The definition of HSDD requires both low sexual desire and associated distress, so distress alone is not the defining factor.
Why women need testosterone after menopause	24:12	Testing for baseline testosterone deficiency is unreliable due to SHBG and blunt testing machines.	While SHBG can affect total testosterone, guidelines recommend measuring free testosterone and SHBG to account for this, so testing is not a complete trap as claimed.

Population patterns (30)

Episode	At	Claim	Why it overshoots
Age not menopause drives testosterone levels	6:43	The decline in testosterone is an effect of age, not menopause.	The study indicates the decline is age-related, but the cross-sectional design and call for further studies mean it does not 'definitively prove' the claim.
Age not menopause drives testosterone levels	9:55	Testosterone hits its absolute lowest point around the ages of 58 to 59.	While the study reports a testosterone nadir around age 58-59 in women, the claim presents this as a universal absolute fact based on a single cross-sectional study.
Age not menopause drives testosterone levels	15:44	The testosterone nadir at age 58-59 perfectly aligns with the peak prevalence of low sexual desire, low arousal, and poor sexual self-image in women.	The study indicates a correspondence between the testosterone nadir and peak prevalence of sexual issues around age 58-59, but the podcast's claim of a 'perfect' and 'exact' alignment overstates the precision of this finding.
Age not menopause drives testosterone levels	18:15	In women aged 70 and above, naturally higher testosterone is linked to better hand grip strength and a significantly lower likelihood of severe depressive symptoms.	The passage reports a lower likelihood of moderate to severe depressive symptoms combined, not severe symptoms alone, so the claim overstates by specifying only severe symptoms.
Hormone Therapy and Endometrial Health in Postmenopausal Women	11:09	Unopposed estrogen use increases endometrial cancer risk from about 1.8 times higher with any use to over 3.5 times higher after five years.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage discusses unopposed estrogen and endometrial cancer risk but gives different magnitude (hyperplasia risk 2-4x) and no time frame, so it does not address the specific claim numbers.
Hormones Not Antidepressants For Menopausal Moods	1:36	These mood symptoms affect anywhere from 10% to 65% of women.	The podcast claims a prevalence range of 10% to 65%, but the provided passage only supports 10%; the 65% upper bound is unsupported by the evidence, making the claim overstated.
Hormones Not Antidepressants For Menopausal Moods	15:04	25% of women are poor absorbers of transdermal hormones.	The podcast claims precisely 25%, but the source says up to 25%, and another passage estimates about 20%, so the claim overstates the precision.
How Testosterone Protects Women From Alzheimer's	0:51	The APOE4 allele is the most dominant genetic risk factor for late-onset Alzheimer's disease.	The passages call APOE the strongest genetic risk factor, not 'most dominant', and the claim's phrasing inflates the certainty by echoing podcast hype.
How Testosterone Protects Women From Alzheimer's	0:51	Women with the APOE4 allele have a more severe biological reaction than men with the same allele.	The podcast states as fact that APOE4 affects women more severely, but the referenced meta-analysis indicates the sex-dependent relationship remains controversial, so the claim is stronger than the published evidence supports.
How Testosterone Protects Women From Alzheimer's	14:51	Longitudinal studies show that women's cognitive advantages in verbal memory and processing speed start to slip during the menopausal transition when systemic estrogen drops.	The podcast portrays processing speed decline as equally settled by longitudinal studies, but the passage indicates the evidence is novel and still uses 'may,' while the link to estrogen drops is not directly demonstrated in those studies.
How Testosterone Shapes Female Biology	9:15	Up until roughly age 13, athletic performance metrics (sprinting speed, vertical leap, broad jump) are virtually indistinguishable between boys and girls.	The study shows male performance already increasing progressively from age 11, so claiming indistinguishability up to age 13 overstates the similarity.
Menopausal Depression and Immune Imbalance	4:12	Perimenopausal depression is specifically linked with increased inflammation.	The passage links perimenopausal status to increased inflammation and inflammation to depression, but does not specifically state that perimenopausal depression is itself linked to inflammation.
Menopausal Transition Increases Depression Risk in Later Life	10:08	The menopausal transition itself is a risk factor.	The claim presents the menopausal transition as a general risk factor, but evidence shows it is not an independent risk factor for dementia and its role in other conditions is often confounded by aging.
Menopausal Transition Increases Depression Risk in Later Life	12:20	The symptomatic menopausal transition seems to add its own independent layer of risk for developing depression later.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage addresses depression risk during the menopausal transition, not the claim that the transition adds independent risk for developing depression later.
Menopausal Transition Increases Depression Risk in Later Life	15:03	The risk is independent of age, socioeconomic factors, and many common chronic medical conditions.	The study supports independence from many chronic conditions and consistent results across age groups, but it lacked data on socioeconomic factors so the claim of independence from socioeconomic factors is unjustified.
Menopausal Transition Increases Depression Risk in Later Life	15:26	Symptomatic menopausal transition appears to be a factor associated with an increased likelihood of facing clinical depression later.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage discusses early menopause as a risk, not symptomatic menopausal transition, so it does not address the specific claim.
Menopause Does Not Crash Your Testosterone	13:59	That low point in testosterone around 58-59 correlates heavily with clinically low sexual desire.	The passage shows a correspondence, not a heavy correlation with clinically low sexual desire, and the claim inflates an observational association into a strong clinical link.
Progesterone Acts as Literal Brain Armor	10:19	Hundreds of millions of people worldwide use synthetic progestins for hormonal contraception and menopausal hormone therapy.	The passage states 'millions' of users, not 'hundreds of millions', so the claim inflates the scale of usage.
Progesterone Acts as Literal Brain Armor	17:46	APOE4 is a major genetic risk factor for Alzheimer's disease and is associated with aggressive decline.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage discusses the APOE gene broadly, not the specific APOE4 allele, and omits the claim about aggressive decline entirely.
Reducing Depression During the Menopausal Transition	2:46	The menopausal transition typically begins around age 47.	The podcast specifies age 47, but the passage indicates perimenopause typically begins around age 45, making the claim slightly overstated.
Testosterone, GABA, and Depression in Women	10:10	Less free testosterone was potentially associated with more severe depression symptoms.	VERDICT UNDER REVIEW. The retrieved passage does not settle this claim. The passage discusses brain activity (ACC and PCC), not depression symptoms, so it does not address the specific outcome in the claim.
The Female Testosterone Pellet Paradox	14:00	Approximately half of daily testosterone production comes from the ovaries and half from the adrenal glands.	The podcast claims half from ovaries and half from adrenals, but the literature shows only ~25% from each, with 50% from peripheral conversion, an overstatement of ovarian/adrenal direct contributions.
Total testosterone is a biological smokescreen	9:59	Bioavailable testosterone shows a strict linear decline across the entire male lifespan, starting from young adulthood.	The claim of a strict linear decline starting from young adulthood is overstated; the passage indicates a decline after 30 (not starting in young adulthood) and notes some studies report minimal decline between 35 and 65, contradicting a strict linear trend across the entire lifespan.
Total testosterone is a biological smokescreen	11:28	Women's circulating testosterone levels are about 20 to 25 times lower than men's.	The podcast says 20-25 times lower, but the source indicates a 15-20 fold difference, so the claim overstates the gap.
Total testosterone is a biological smokescreen	13:39	Bioavailable testosterone in women declines linearly from age 30 to 96.	The claim states a linear decline from age 30 to 96, but the evidence shows a decline that levels off or increases after the sixth decade, so the linearity is overstated.
Why Hormone Therapy Stops Midlife Suicide	0:00	In the UK, the demographic with the highest suicide rate among females is midlife women aged 45 to 49.	The claim singles out the 45-49 age bracket as the highest, but the passage shows peak rates also in the 50-54 group, making the claim overly specific.
Why total testosterone is a meaningless metric	9:30	The HSD3B1 genetic variant is detrimental for keeping hair.	The claim presents the variant as universally detrimental for keeping hair, but the passage only shows an association with hair loss in a specific group (women with PCOS, particularly overweight/obese).
Why women have more testosterone than estrogen	0:34	Healthy pre-menopausal women have 15 to 20 times more testosterone circulating than estrogen.	The ratio of testosterone to estrogen in premenopausal women varies widely, from near 1:1 at ovulation to higher ratios, so claiming a constant 15-20x is an overstatement.
Why women have more testosterone than estrogen	2:27	Androgen decline starts a steady downward slope when a woman is in her mid-30s.	The paper says the decline intensifies, not that it is a steady downward slope, so the podcast overstates the constancy of the decline.
Why women have more testosterone than estrogen	2:50	The postmenopausal ovary continues to produce 40 to 50% of a woman's testosterone.	The study shows only a 27% lower testosterone after oophorectomy, not 40-50%, so the claim overstates the ovarian contribution.

Dose and delivery (14)

Episode	At	Claim	Why it overshoots
How muscle strength saves your brain	15:08	The RDA of 0.8 grams of protein per kilogram is dangerously low for older adults.	The podcast asserts international guidelines are adamant that 0.8 g/kg is dangerously low, but the passage states that WHO and EFSA recommend 0.83 g/kg for all adults, with only some researchers arguing it might underestimate older adults' needs.
How muscle strength saves your brain	15:23	Older adults require between 1 and 1.3 grams of protein per kilogram to maintain and gain muscle.	The passages recommend 1.0-1.2 g/kg/day for healthy older adults and higher for illness, but no source supports exactly 1.3 g/kg/day as a specific requirement for all older adults to maintain and gain muscle.
Muscle Protein Synthesis_ Nutrition and Exercise Responses	8:33	Even after exercise, consuming more than about 20 grams of protein at once does not further increase muscle protein synthesis; excess amino acids are oxidized.	The claim asserts a strict 20 g saturation limit, but the passage indicates a range of 20-40 g after exercise, depending on individual factors, making the claim overly absolute.
Testosterone Therapy for Women's Desire and Mood	23:49	Transdermal preparations avoid dangerous peaks and troughs in hormone levels.	While transdermal testosterone offers more stable levels, it can still produce supraphysiologic peaks at higher doses, so it does not completely avoid dangerous peaks.
Testosterone Therapy for Women's Desire and Mood	26:30	A safe physiological dose of testosterone for women is about 300 micrograms (0.3 mg) per day.	The passage describes a specific study dose, not a universally safe physiological target dose, and notes androgenic adverse events and uncertain long-term effects.
Testosterone is the primary female hormone	6:05	The 299 ng/dL level is nearly six times the normal upper limit of 55 ng/dL.	The podcast claims the level is nearly six times the upper limit, but the passage gives a range of 4-6 times, so the podcast presents a stronger, more definitive ratio than the evidence supports.
Testosterone is the primary female hormone	16:05	A 50-milligram testosterone pellet releases exactly 0.3 to 0.4 milligrams per day into the bloodstream.	The passage says 'approximately', not 'exactly', so the podcast overstates the precision of the release rate.
The Dangerous Convenience of Testosterone Pellets	14:25	It takes four to six months for a testosterone pellet to fully exit the system.	The cited study supports a 4-5 month exit, but other evidence shows levels still elevated after 6 months, making the blanket 4-6 month claim overly firm.
The Female Testosterone Pellet Paradox	14:39	Only 150 to 200 milligram pellets release a daily dose that definitively exceeds natural synthesis.	The passages confirm that 150-200 mg pellets produce supraphysiologic levels, but they do not support the claim that such doses ‘definitively’ exceed natural synthesis in all contexts or that only these large pellets do so; the evidence is from observational studies with noted limitations, making the claim overstated.
The Risks of Female Testosterone Pellets	3:25	The vast majority of women are getting testosterone off-label through compounded subcutaneous pellets.	The claim that the 'vast majority' of women use pellets is overstated; the cited source estimates pellets account for only 10-15% of testosterone prescriptions for women, contradicting the claim's magnitude.
The Risks of Female Testosterone Pellets	4:31	After pellet insertion, serum testosterone levels reach 100 to nearly 300 ng/dL.	The podcast claims levels reach 100-300 ng/dL 'right after insertion,' but studies show this peak occurs around 4 weeks post-insertion, not immediately.
Why testosterone delivery is the drug	2:22	Prescribing short-acting testosterone esters on a biweekly schedule is biologically inappropriate.	The passages state that biweekly dosing can be acceptable for some patients, so calling it biologically inappropriate and senseless exaggerates the evidence.
Why testosterone delivery is the drug	6:12	The published literature overwhelmingly supports dividing the total testosterone dose into smaller, more frequent microdoses (e.g., weekly, twice weekly, every other day) to smooth serum levels.	The podcast claims the literature overwhelmingly supports microdosing, but the passage explicitly states evidence is limited, lacks direct comparative trials, and does not support a universal schedule, making the claim overstated.
Why testosterone delivery is the drug	9:37	Testosterone undecanoate must be taken with dietary fat.	The claim that testosterone undecanoate must be taken with dietary fat is overstated because newer oral formulations like Tlando do not require fat for absorption.

Diagnosis (1)

Episode	At	Claim	Why it overshoots
Why Hormone Therapy Stops Midlife Suicide	9:10	Perimenopausal depression is characterized by acute volatility, highly episodic, with sudden severe crashes of despair, intense paranoia, or explosive irritability that feels entirely alien.	The claim exaggerates the episodic and volatile nature; the passage notes intense bouts of sadness and irritability but not sudden severe crashes, paranoia, or an alien feeling.

The 65 contradicted claims, and why the number needs care

A paper in the library states the opposite. This count is not 65 podcast errors, and presenting it that way would repeat the overreach this audit exists to catch. Reading through them, they fall into three groups:

Real errors. The podcast states something untrue, or contradicts itself.
Inter-study disagreement. The podcast reported its own source faithfully and a different paper in the library disagrees. That is a fact about the literature, not a fault in the episode, and it is often the more useful finding: it marks where a script should say "studies conflict".
Retrieval misses. The checker matched an off-target passage.

Separating them needs each episode's actual source resolved, which has not been done. Until it is, treat this table as a list to investigate, not a verdict.

Episode	At	Claim	What the library says
Hormone Therapy and Endometrial Health in Postmenopausal Women	9:57	When MHT is started relatively early after menopause, used at lower doses, and combined with progesterone, it can be relatively safe for many women.	A large meta-analysis shows increased breast cancer risk even with early initiation, directly contradicting the claim that such use is relatively safe.
Hormone therapy reduces mortality after sixty-five	2:31	Over 42% of women aged 60 to 65 in the 2024 study had significant vasomotor symptoms.	The passage reports only 6.5% for that age group, directly conflicting with the claimed over 42%.
Hormone therapy reduces mortality after sixty-five	6:43	Estrogen monotherapy was associated with a 2% reduction in dementia risk.	The passage states a 34% risk reduction, not 2%, directly contradicting the claim.
Hormone therapy reduces mortality after sixty-five	8:36	EPT lowers ovarian cancer risk by 21%.	The passage indicates hormone therapy increases ovarian cancer risk, directly opposing the claim of a 21% risk reduction.
Hormone therapy reduces mortality after sixty-five	8:50	EPT with synthetic progestin increases breast cancer risk by 10 to 19%.	The meta-analysis found a 44% increased risk for EPT, which is much higher than the claimed 10-19%.
Hormone therapy reduces mortality after sixty-five	10:09	Low and medium doses are vastly superior for senior women.	The meta-analysis found that high-intensity exercise was superior for bone density in osteoporosis patients, directly opposing the claim that low and medium doses are vastly superior.
Hormone therapy reduces mortality after sixty-five	10:57	Estradiol significantly outperformed conjugated equine estrogen in reducing mortality and breast cancer risk.	This study found that conjugated equine estrogen alone had a stronger association with reduced breast cancer risk than bioidentical estrogen alone, directly contradicting the claim that estradiol outperforms CEE.
Hormone therapy reduces mortality after sixty-five	14:28	Low-dose transdermal or vaginal therapy virtually erases the excess breast cancer risk.	The meta-analysis directly contradicts the claim by showing that transdermal estrogen does not reduce breast cancer risk compared to oral estrogen, meaning it does not 'virtually erase' the excess risk.
Hormones Not Antidepressants For Menopausal Moods	10:27	The study included 920 women and used body-identical hormones exclusively.	The study included a synthetic progestin (levonorgestrel IUD) alongside body-identical hormones, contradicting the claim of exclusive use.
Hormones Not Antidepressants For Menopausal Moods	18:18	Standard clinical guidelines imply that testosterone is unnecessary for women's mental health.	Guidelines do recommend testosterone for low sexual desire, contradicting the claim that they imply it is unnecessary for women's mental health.
How Testosterone Protects Women From Alzheimer's	4:55	Preclinical studies show that testosterone protects the brain's infrastructure.	The claim that testosterone protects the brain's infrastructure is directly contradicted by a passage stating that in male rats, testosterone impairs blood-brain barrier function and increases neuronal death and inflammation.
How Testosterone Protects Women From Alzheimer's	21:16	In a robust data set, men's cognition was completely unaffected by their testosterone levels.	The claim is contradicted by evidence linking low testosterone to poorer cognition and showing that testosterone supplementation improves memory in men.
How Testosterone Shapes Female Biology	17:40	In the HSR mouse model, female mice overexpressing the androgen receptor in muscle tissue, when exposed to androgens, rapidly gained lean mass and grew larger glycolytic muscle fibers.	The podcast claims female mice rapidly gained lean mass and grew larger muscle fibers, but the passage states that testosterone treatment in the same HSAAR mouse model induced drastic declines in body mass and motor function, not growth.
How muscle strength saves your brain	11:52	Subjecting aging muscle to heavy, high-intensity loads dramatically increases the risk of a tear or joint injury.	The cited passage warns that low-load training with high velocity increases injury risk, directly opposing the claim that heavy, high-intensity loads dramatically increase risk.
Menopause Does Not Crash Your Testosterone	12:53	The only hormone that dropped significantly due to menopause was androstenedione.	The passage states that estradiol drops significantly, so androstenedione is not the only hormone affected.
Menopause Does Not Crash Your Testosterone	19:11	A woman's body naturally starts increasing testosterone again in her 60s to potentially protect her heart and preserve her muscles.	Testosterone levels decline over a woman's lifetime, not increase in her 60s, contradicting the claim.
Precision Hormones and Nanotechnology for Depression	9:55	The cream brings testosterone levels back up to where they were in the woman's 20s or 30s.	The claim that the cream restores testosterone to levels seen in a woman's 20s or 30s is contradicted by evidence showing testosterone declines with age; no passage supports that the cream achieves this specific rejuvenation.
Precision Hormones and Nanotechnology for Depression	10:17	Hypoactive sexual desire disorder is currently the only condition the FDA formally recognizes testosterone for in women.	The FDA has not approved any testosterone product for women, so it does not formally recognize testosterone for hypoactive sexual desire disorder or any other condition.
Progesterone Acts as Literal Brain Armor	3:28	Allo operates on an inverted U-shaped curve: low and high doses are calming, but moderate doses cause severe anxiety, negative mood, and aggression.	The podcast claims moderate ALLO levels cause severe anxiety, but the study finds that high and low levels are linked to worse mood, contradicting the claim.
Progesterone Acts as Literal Brain Armor	6:06	Women with PMDD have normal progesterone and allo levels, identical to women with typical PMS.	The passage indicates that women with PMDD have an altered ALLO/progesterone ratio and metabolism, contradicting the claim that their progesterone and ALLO levels are identical to women with typical PMS.
Progesterone Acts as Literal Brain Armor	10:00	A moderate dose of natural progesterone causes PMDD.	The passages describe progesterone as a potential treatment for PMDD, directly contradicting the claim that it causes PMDD.
Progesterone Acts as Literal Brain Armor	10:27	Synthetic progestins effectively control ovulation and protect the uterine lining.	The claim states synthetic progestins 'effectively control ovulation,' but the evidence shows that many progestin-only contraceptives do not consistently suppress ovulation, and IUDs typically do not suppress ovulation at all, contradicting the blanket assertion.
Progesterone Acts as Literal Brain Armor	14:18	Stroke incidence is noticeably lower in women during their fertile years than in men.	The evidence shows that in multiple age groups during fertile years, women had a higher or similar stroke incidence compared to men, directly contradicting the claim of noticeably lower incidence.
Progesterone Acts as Literal Brain Armor	14:22	Stroke recovery rates are better in women during fertile years than in men.	The passage directly states that women have poorer functional recovery after stroke, contradicting the claim that recovery rates are better in women during fertile years.
Progesterone Acts as Literal Brain Armor	16:26	The Protect the Third and Synapse trials failed to show clinical benefit.	VERDICT UNDER REVIEW. The passage retrieved for this claim does not appear to be about it. The passage discusses memory benefits from sustained engagement, not the Protect the Third or Synapse trials.
Testosterone Therapy for Women's Desire and Mood	3:11	Consensus guidelines strongly recommend against routinely measuring circulating testosterone levels to diagnose HSDD.	A passage directly recommends measuring testosterone as part of the diagnostic workup for HSDD, contradicting the claim that consensus guidelines strongly advise against it.
Testosterone Therapy for Women's Desire and Mood	6:01	Testosterone production generates about 0.2 to 0.25 milligrams per day in premenopausal women.	The podcast claims 0.2-0.25 mg/day, but the passage states 0.6-0.8 mg/day, directly contradicting the claim.
Testosterone for female sexual desire	9:50	There is virtually no high quality safety data exceeding 24 continuous months of use.	The claim is contradicted by high-quality evidence showing safety data for the levonorgestrel-releasing intrauterine system (LNG-IUS) beyond 24 months, as a meta-analysis supports its use for up to 5 years.
Testosterone for female sexual desire	9:56	We do not know the long-term systemic impacts, specifically cardiovascular risks or breast cancer risks, of this therapy beyond 24 months.	The passage states that long-term systemic estrogen therapy has known increased risks of breast cancer, directly contradicting the claim that we are completely in the dark about such risks beyond 24 months.
Testosterone for female sexual desire	13:34	Testosterone therapy during the transition may break the cycle of low desire and pain by boosting arousal and improving tissue health.	A clinical trial found that testosterone therapy improved desire but not pain; pain improved in the placebo group, contradicting the claim that testosterone breaks the pain cycle.
Testosterone for female sexual desire	19:42	In the transdermal patch studies, doses ranged from 10 milligrams to 50 milligrams.	The passage reports transdermal estradiol patch doses in micrograms, not milligrams, with doses of 14 and 50 micrograms per day, contradicting the claim of 10-50 milligrams.
Testosterone is the primary female hormone	14:03	Dosage completely dictates the side effects.	This passage shows that dosage influences side effects, but other passages make clear that factors beyond dosage, such as individual patient characteristics and type of hormone therapy, also affect side effects, so the claim that dosage 'completely' dictates side effects is contradicted by the literature.
Testosterone is the primary female hormone	17:30	Testosterone therapy itself is not inherently dangerous.	Testosterone therapy can cause erythrocytosis, a condition guidelines deem potentially dangerous and may require stopping therapy, directly countering the claim of no inherent danger.
Testosterone therapy for female sexual desire	11:44	A systematic review highlighted that testosterone alone doesn't show significant psychological benefit outside sexual function.	The podcast claims no significant psychological benefit beyond sexual function, but the cited review and other passages consistently report improvements in sexual desire, arousal, and distress, which are psychological outcomes.
Testosterone therapy for female sexual desire	16:45	We lack multi-decade epidemiological data to definitively clear it of cardiovascular or breast cancer risks.	The claim that we lack multi-decade epidemiological data is directly contradicted by the cited passage, which states that research over the past 25 years has provided valuable information on both breast cancer and cardiovascular risks from hormone therapy.
Testosterone, GABA, and Depression in Women	13:14	Having free testosterone levels in a certain range might be associated with less severe depression symptoms.	A randomized trial found that raising free testosterone levels did not reduce depression severity, directly contradicting the claim of an association with less severe symptoms.
The Dangerous Convenience of Testosterone Pellets	14:38	The FDA issues severe cardiovascular warnings for testosterone therapy.	The FDA removed boxed warnings about cardiovascular risk for testosterone therapy, contradicting the claim of severe cardiovascular warnings.
The Hidden Androgens Your Blood Test Misses	16:53	Muscle hypertrophy was perfectly predicted by the proportion of androgen receptor that localized into the cell's nucleus.	The study found that nuclear-localized AR proportion was associated with baseline muscle mass, but specifically not with training-induced hypertrophy, directly contradicting the claim that growth was perfectly predicted by it.
The Risks of Female Testosterone Pellets	5:47	Testosterone pellet insertion is not easily reversible if a bad reaction occurs.	The passage states that pellet removal (explant) is a management option for adverse reactions, directly contradicting the claim that it cannot be taken out.
Total testosterone is a biological smokescreen	9:31	Total testosterone in men remains incredibly stable until the age of 70.	Total testosterone in men actually declines gradually after age 40, contradicting the claim of stability until 70.
Total testosterone is a biological smokescreen	9:53	Total testosterone accelerates its decline only after age 70.	The claim that total testosterone decline accelerates only after age 70 is contradicted by evidence of a steady decrease from the 30s onward.
Total testosterone is a biological smokescreen	11:45	Testosterone is vital for female cellular signaling, bone health, and muscle maintenance.	The passage shows that female mice lacking androgen receptors maintain normal lean mass, indicating testosterone is not vital for muscle maintenance, directly contradicting the claim.
Total testosterone is a biological smokescreen	12:54	SHBG in women decreases slightly before menopause and then accelerates sharply upward as they get older.	The claim that SHBG accelerates sharply upward after menopause is directly contradicted by the passage stating it declines only slightly across menopause.
Unpacking Female Desire_ The Surprising Truth About Estradiol and Testosterone	3:02	Women received testosterone doses of 75 to 350 milligrams per week.	The podcast claim states doses of 75-350 mg per week, but the cited study used only 300 micrograms per day, equivalent to about 2.1 mg per week, which is far lower.
Unpacking Female Desire_ The Surprising Truth About Estradiol and Testosterone	10:12	The concept of female androgen insufficiency was never empirically established.	The passage describes androgen insufficiency as a recognized condition with documented causes, directly contradicting the claim that the concept was never empirically established.
Unpacking Female Desire_ The Surprising Truth About Estradiol and Testosterone	12:48	Only two double-blind randomized trials have looked at testosterone alone in postmenopausal women for sexual desire.	The systematic review identifies 7 RCTs in postmenopausal women, not just two, directly contradicting the claim.
What testosterone does to your brain	10:24	Testosterone does not elevate a healthy person's cognitive function above baseline.	A randomized trial in healthy older men found that moderate testosterone increases improved memory, directly contradicting the claim that testosterone does not elevate cognition above baseline in healthy people.
Why Hormone Therapy Stops Midlife Suicide	19:05	If the underlying mechanism of distress is a biological hormone crash, psychological treatments will never heal it.	The passage states that even when biology is the primary cause, psychological factors can maintain distress, and combination therapy including psychological treatment can be beneficial, contradicting the claim that psychological treatments never heal.
Why Testosterone Lab Results Are Unreliable	2:58	A single testosterone measurement taken in the afternoon completely misrepresents a person's average biological state.	That passage shows a single blood measurement can reliably represent average androgen (including testosterone) levels, directly contradicting the claim that a single afternoon measurement completely misrepresents average biological state.
Why Testosterone Needs Estrogen to Burn Fat	8:07	A 14% increase in muscle mass is roughly equivalent to the gains from 8 to 16 weeks of dedicated heavy resistance training in humans.	A 12-week resistance training study in postmenopausal women showed a 3.9% muscle cross-sectional area increase, far less than 14%, contradicting the claimed typical gain.
Why Testosterone Needs Estrogen to Burn Fat	14:19	Female testosterone levels peak between ages 20 and 25 and then slowly decline.	The passage states female testosterone peaks around age 30, while the podcast claims the peak is between 20 and 25.
Why total testosterone is a meaningless metric	1:40	The total testosterone number on your blood test might not matter for you at all.	Total testosterone levels are monitored to prevent excessive dosing and side effects, so the number matters.
Why total testosterone is a meaningless metric	9:46	Local testosterone synthesis in the scalp is completely independent of what ovaries or adrenal glands put into the bloodstream.	Local testosterone synthesis in non-ovarian tissues like the scalp depends on precursors from the ovaries and adrenal glands, contradicting the claim of complete independence.
Why women have more testosterone than estrogen	14:12	The placenta is densely packed with aromatase and rapidly converts maternal testosterone into harmless estrogen, preventing fetal virilization.	The passage indicates that maternal testosterone does cross the placenta, so it is not entirely converted to estrogen before reaching the fetus.
Why women have more testosterone than estrogen	17:22	Standard blood testosterone tests measure total hormone including both active and inactive fractions, so total testosterone does not reflect biologically active levels.	The provided literature states that total testosterone is considered the main biomarker and there is insufficient evidence that free testosterone is the biologically active fraction, directly contradicting the claim that total testosterone does not reflect active levels.
Why women have more testosterone than estrogen	19:46	Testosterone therapy must be guided by clinical symptoms and safety tolerability rather than lab targets.	The passage states that delaying a procedure is indicated when testosterone levels are supraphysiologic or hematocrit exceeds a specific lab target, which directly contradicts the podcast's claim that therapy should not be guided by lab targets.
Why women have more testosterone than estrogen	22:10	Keeping a 60-year-old woman's testosterone within a normal youthful blood range might be underdosing her tissues if receptor resistance is present.	The claim suggests normal youthful testosterone levels may be too low due to receptor resistance, but the guidance explicitly warns against exceeding the premenopausal range to avoid androgenic side effects, indicating normal levels are not underdosing.
Why women have zero testosterone options	4:44	Testosterone has been licensed for use in women in England and Australia for more than 60 years.	The claim asserts that testosterone is licensed for women in England, but this passage states it is not licensed outside Australia, contradicting the England portion of the claim.
Why women have zero testosterone options	14:48	Compounded bioidentical hormones are highly regulated at both state and federal levels today.	The passage explicitly states that compounded bioidentical hormone therapy has not been formally regulated, directly contradicting the claim of high state and federal regulation.
Why women have zero testosterone options	16:40	There is zero evidence testosterone administration promotes endometrial cancer.	The study cited in the passage found that testosterone increased the risk of endometrial cancer, directly contradicting the claim that there is zero evidence for this effect.
Why women need testosterone after menopause	4:25	The postmenopausal ovary accounts for 40 to 50 percent of a woman's testosterone production well into later years.	The passage directly states that after menopause testosterone comes mainly from adrenals and peripheral tissues, not the ovaries, contradicting the claim of 40-50% ovarian production.
Why women need testosterone after menopause	9:46	There is no absolute blood level that defines a deficiency.	The claim is contradicted because absolute blood levels, such as below 340 nmol/L for folate, do define deficiency.
Why women need testosterone after menopause	11:23	Researchers gave postmenopausal women 300 micrograms per day of transdermal testosterone.	The podcast claims a specific dose of 300 micrograms per day of transdermal testosterone was given, but the cited study included two dose arms (150 and 300 micrograms) and placebo, not a single arm of 300 micrograms.
Why women need testosterone after menopause	13:23	At superphysiologic levels, testosterone promotes vasoconstriction, tightening blood vessels.	The passage directly states testosterone causes vasodilation, the opposite of the claimed vasoconstriction.
Why women need testosterone after menopause	22:41	Oral testosterone is heavily discouraged.	Modern oral testosterone formulations like testosterone undecanoate are effective and safe, directly contradicting the claim that oral testosterone is heavily discouraged.

What actually goes wrong in these podcasts

Not invented statistics. Almost every number traced back to a real paper. The failure modes are subtler and survive a spot check:

Single-source confidence. 18 of the 36 original episodes were generated from one paper, then given a title asserting a general truth. One study becomes settled science with no signal that anything disagrees.

Dropped distinctions. The clearest case: an episode reports that combined hormone therapy lowers ovarian cancer risk by 21%. Its source attributes that specifically to synthetic progestin, and reports that micronized progesterone showed benefit for heart failure only. The podcast said "EPT" and the distinction that changes the answer disappeared.

No sense of evidence hierarchy. A claims-database analysis is delivered with the confidence a randomised trial would earn.

No awareness of its own gaps. It never says "other studies disagree" because it has no way to know.

Method, and where it is weak

Transcription: faster-whisper large-v3, local GPU, 975,000 characters, no failures. Hormone terminology was spot-checked because a misheard hormone name would poison everything downstream.

Claim extraction and judgement: DeepSeek via OpenRouter. Retrieval: BM25 over 16,894 passages from the 551 library notes that hold real text.

Known weaknesses, stated plainly:

Regulatory and legal claims are unreliable here. Drug licensing moves faster than the literature describing it. One episode was flagged for saying testosterone is licensed for women in England; the flag was wrong, the product is available there and UK approval has since moved. Physiology and effect sizes are where this method is trustworthy.
CONTRADICTED conflates three different things, as described above.
An earlier run lost 17% of claims to a parsing fault, and the losses were biased toward claims the checker could actually decide, because deciding one meant quoting a paper. Fixed before the full run; the numbers here are from the fixed version.
Only high-risk claims were checked. The other 1,180 were not.

Published to Annette's hub. Rebuilt from the source markdown, so edit the source and rerun rather than editing this page.